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Abstract 
 
This thesis focuses on im proved processing methods for enhanced m echanical 
properties in polymer nanocomposites, and controlled drug release in polymer based 
delivery systems. Supercritical carbon dioxide assisted mixing was successfully used 
in preparation of polypropylene/sepiol ite and polypropylene/m ultiwall carbon 
nanotube nanocomposites. Relatively hom ogeneous dispersed and well separated 
nanofillers were obtain ed throughout the PP matrix. A better preservation of 
nanofiller lengths was observed in the scCO 2 assisted mixing. Mechanical property 
studies showed a marked increase in Young’ s modulus and tensile  strength with the 
addition of nanofillers. More in terestingly, techniques usually designed to achiev e 
high quality PP nanocomposites, such as th e use of masterbatches, maleic anhydride 
grafted polypropylene compatibilizers or polymer coated MWNTs are not needed to 
achieve equivalent mechanical properties with scCO2 assisted m ixing. ScCO2 was 
also used as a foam ing technique to modify the traditional cured poly(ethyl 
methacrylate/tetrahydrofurfuryl methacrylate) system for a controlled  release of 
chlorhexidine. Highly p orous structures were p roduced and chlorhexidine released 
from scCO2 foamed samples was more than 3  times higher than traditionally cure d 
samples. By altering the proc essing conditions, such as CO 2 saturation tim e and 
depressurization time the CX releas e rate was altered. Finally , the electrospinning 
method was combined with the layering encap sulation technique in order to enable 
the incorporation of water-soluble drugs in  poly(lactic-co-glycolic acid) fibres for 
biomedical applications. Water-soluble drug, Rhodamine 6G or protein bovine serum 
albumin, loaded calcium carbonate microparticles were successfully incorporated i n 
PLGA fibres and a bead and string structured composite fibres.  
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Chapter 1 
 
Introduction 
 
 
 
 
 
1.1 Background Information for Polymer Matrix Composites 
 
Composites refer to materials composed of two or more distinct phases (matrix phase 
and dispersed phase) each having significantly different physical or chemical 
properties1. Composites are around us everywhere. A tree is a good example of a 
natural composite, consisting of cellulose (the fibrous material) and a matrix of lignin 
(a natural polymer). A pavement is a man-made composite formed with steel and 
aggregate reinforced asphalt concrete. Composites started attracting more and more 
attention since their successful development for aerospace use in the 1960s. Since 
then, further exploration on composites has led to their use in the automotive, 
biomedical, and sporting goods markets. In addition, more recently, increased usage 
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of composite materials can be seen in the rehabilitation, repair, and retrofit of civil 
infrastructure--including, for example, as replacement bridge decks and as wrapping 
of concrete columns. 
 
Depending on the nature of the matrix, composites can be classified into metal 
matrix composites (MMCs), ceramic matrix composites (CMCs) and polymer matrix 
composites (PMCs)1. Among them, PMCs are most common and widely applied in 
commercial applications. A wide range of fillers have been employed as the 
dispersed phases in the polymer matrix for enhanced performance with regard to the 
mechanical, thermal and electrical properties2. In addition, PMCs are also the 
preferred materials in bioengineering and biomedical research as witnessed by their 
use in tissue engineering and advanced drug delivery systems. This is because they 
can be designed to be non-toxic, biocompatible and biodegradable2. 
 
1.1.1 Polymer Composites for Improved Mechanical Properties  
 
There has been intensive research carried out for enhanced mechanical properties - 
for example, higher strength and higher modulus1. Conventional composites are 
normally filled with micro-scale fillers including metals, ceramics and high modulus 
fillers. However, enhanced mechanical properties are often compromised in terms of 
embrittlement of the polymer due to stress concentrations1. By comparison with 
conventional micro-scale fillers, nano-scale fillers give rise to significant 
improvements in the toughness of the composites along with other properties 
including thermal stability, flame retardancy, chemical resistance, electrical 
conductivity and optical clarity3. The differences should be related to the extremely 
small size of the fillers giving them unique properties, and a better interaction with 
the polymer matrix. 
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The most promising nanofillers are those such as carbon nanotubes (CNTs) or 
nanoclays, due to their high aspect ratios, since only a small amount of them is 
needed to reinforce the polymer matrix. Mechanical reinforcement by CNTs or clays 
in polymer composites has been extensively investigated4-9. However, the effective 
use of these nanofillers is far from perfect since they have extremely large surface 
area which causes agglomerates. The major challenge is in the breaking down of 
bundles of aggregated nanofillers and in reaching a fine dispersion in the selected 
polymer matrix. In particular, the most common composite processing method, melt 
compounding, is less effective at dispersing nanofillers such as CNTs and clays. 
Moreover, the high viscosity of the composite caused by the addition of nanofillers 
limits the nanofiller loadings and the high shear rates and high temperatures involved 
cause the thermal instability of the polymers4,9. 
 
1.1.2 Polymer Systems for Controlled Release in Drug Delivery 
 
In addition to the enhanced mechanical properties, polymer systems are widely 
applied in advanced drug delivery systems. Normally, a therapeutic agent is 
administered in a high dose at a given time and repeated later. This sometimes results 
in undesirable (e.g. toxic) side-effects. It is inconvenient and patient compliance is 
often poor10. For these reasons, interest has focused on developing sustained-release 
devices to deliver a drug for prolonged time periods and in a controlled manner. The 
sustained-release of drugs can be achieved by the polymer delivery systems in which 
the polymer acts as a drug carrier. Also, polymer delivery systems can be designed 
for drug targeting, which is to deliver drugs to a specific tissue or organ using 
polymer carriers11.  
 
Polymer delivery systems can be classified into non-biodegradable and 
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biodegradable delivery systems. The first polymer drug release system was based on 
non-biodegradable polymers designed by Folkman and Long in 196412. They 
reported the use of silicone for sustained release. Since then, many 
non-biodegradable polymers have been studied and used for controlled drug 
delivery13. On the other hand, biodegradable delivery systems have attracted more 
and more attention. Biodegradable delivery systems can be metabolised and excreted 
by natural pathways, so there is no need for surgical removal. The polymer is used as 
protection for the drug during its transfer through the body until it is released, or used 
to control the release rate of the drug. The polymers such as polycaprolactone, 
polylactides (PLA), polyglycolides (PGA), and copolymers 
poly(lactide-co-glycolides) (PLGA)14-16 have been actively studied.  
  
1.2 Objectives 
 
This thesis focuses on improved processing methods for polymer-based systems. 
Attention is paid on improved mechanical properties for polymer nanocomposites 
and controlled drug release for polymer based delivery systems. Particularly in melt 
compounding nanocomposite processes, the achievement of well dispersed 
nanofillers in the polymer matrix is a major challenge. Supercritical carbon dioxide 
(scCO2) processing offer an interesting alternative to overcome some of the 
challenges in traditional melt compounding such as the occurrence of high viscosities, 
high temperatures and high shear stress. The plasticization of scCO2 could reduce the 
polymer viscosity, decrease the melting temperature, and hence increase the 
processiblity of nanocomposites and lead to a better dispersion of nanofillers17. In 
drug delivery, the sustained release is essential and is the ultimate goal for both 
nonbio- and biodegradable polymer systems. Changing the morphology of the 
polymer matrix, porosity for example, is believed to have a great impact on the drug 
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release profile. It is expected that the porous structures created by the scCO2 foaming 
process should enhance the release of the drug. On the other hand, a second barrier 
around the drug, created by layer-by-layer (LbL) encapsulation, could give better 
protection to it and may establish a new method for delivering water soluble drugs. 
Hence, the main objectives of this thesis are:  
 
• To investigate the potential benefits of using scCO2 for a better dispersion of 
nanofillers in nanocomposites 
• To study the foaming of traditional cured polymer systems by scCO2 techniques 
and its impact on the drug release profile 
• To fabricate a drug release device for water soluble drugs by a combined 
encapsulation and electrospinning technique 
 
1.3 Outline of the Thesis 
 
There are two major parts in this thesis. Part A concentrates on the processing of 
polypropylene (PP) nanocomposites with scCO2 assisted mixing. The nanofillers 
studied are multiwall carbon nanotubes (MWNTs) and sepiolite clays. Chapter 2 will 
introduce the materials used in this study. An introduction in polymer 
nanocomposites including their properties, the processing methods and the effective 
properties of nanofillers in the composites will be presented. Chapter 3 will describe 
the preparation of PP/sepiolite nanocomposites using scCO2 assisted mixing. The 
resulting properties of the nanocomposites will be compared with those from 
traditional melt compounding methods. In Chapter 4, preparation of PP/CNT 
nanocomposites using scCO2 assisted mixing will be discussed in detail. The 
potential benefits of using scCO2 in this system will be investigated. 
Micromechanical modelling will be used to analyse the effective properties of the 
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MWNTs in the nanocomposites. 
 
Part B investigates the processing of polymer delivery systems for the controlled 
release of drugs. Chapter 5 will give an overview of drug delivery systems. The 
designs and types of drug delivery systems will be introduced. Theoretical analysis 
using kinetic equations to analyse the drug release mechanism will be described as 
well. Chapter 6 will present the preparation of a foamed poly(ethyl 
methacrylate/tetrahydrofurfuryl methacrylate) (PEM/THFM) polymer system by 
scCO2 foaming processing. Chlorhexidine (CX) will be used as the dispersed drug. 
The scCO2 foaming condition processed on the traditional cured CX-PEM/THFM 
polymeric system will be investigated for the optimum release of CX from the 
PEM/THFM matrix. The kinetics of the drug release will also be studied. In Chapter 
7, a biodegradable polymer, PLGA, will be chosen for the drug release device. Water 
soluble drug loaded calcium carbonate (CaCO3) microparticles incorporated in 
PLGA fibres will be prepared by a combined layering encapsulation and 
electrospinning technique. The morphology of the fibres will be studied. The drug 
release behavior, the degradation of the fibre and the bioactivity of the drug will be 
investigated in detail. Finally, Chapter 8 will summarize the main conclusions and 
will address possible research directions for the future. 
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Chapter 2 
 
Polymer Nanocomposites and ScCO2 
 
 
 
 
 
2.1 Introduction 
 
In recent years polymer nanocomposites have attracted great interest in 
academia1.The attractiveness of this new class of material lies in the large 
improvements in both mechanical and thermal properties, as well as in gas barrier 
and fire resistance. First, the nanofillers and polymer matrices used in this study are 
introduced. Then polymer nanocomposites and the processing methods used are 
overviewed. 
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2.2 Nanofillers 
 
The term ‘nanofillers’ is vague and no precise definition exists. Nanofillers are 
understood, in essence, to be additives in solid form, which differ from the polymer 
matrix in terms of their composition and structure. Nanofillers are of the order of 100 
nm or less in at least one dimension Fig. 2.1 shows the nanometre domain in the 
context of some common microscopic objects. 
 
Fig. 2.1 The nanometre domain relative to some common architectures1 
 
Nanofillers are often added to enhance one or more of the properties of the polymer. 
Inactive fillers or extenders raise the quantity and lower the prices, while active 
fillers bring about targeted improvements in certain mechanical or physical 
properties. Common nanofillers include calcium carbonate, ceramic nanofillers, 
carbon black, CNTs, carbon nanofibres, cellulose nanowhiskers, nanoclays, gold 
particles, kaolin, mica, silica, silver nanoparticles, titanium dioxide, etc. Because of 
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their impressive intrinsic mechanical properties, nanoscale dimensions and high 
aspect-ratio, nanofillers such as CNTs or nanoclays are the most promising due to the 
fact that small amounts (less than 5 %) of them can provide the resulting 
nanocomposite material with significant property improvements.  
 
2.2.1 Carbon Nanotubes (CNTs) 
 
CNTs are considered to be ideal candidates for a wide range of applications in 
materials science because of their exceptional mechanical, thermal, and electronic 
properties2. Carbon nanotubes exist as two types of structures: singlewall carbon 
nanotubes (SWNTs) and multiwall carbon nanotubes (MWNTs). Fig. 2.2 shows the 
schematic pictures of different types of carbon nanotubes. SWNT can be considered 
as graphene sheet rolled cylinders of covalently bonded carbon atoms with very high 
aspect ratios of 1000 or more. MWNTs consist of a number of graphene cylinders 
concentrically nested like rings in a tree trunk with an interlayer distance of ~0.34 
nm.  
 
               (a)                           (b) 
Fig. 2.2 A schematic illustration of different types of carbon nanotubes. (a) 
single-walled carbon nanotubes and (b) multi-walled carbon nanotubes3 
 
Chapter 2. Polymer Nanocomposites and ScCO2 
 34
2.2.1.1 The Structure of Carbon Nanotubes  
 
Based on the geometry of the carbon bonds around the circumference of the carbon 
nanotube, CNTs are divided into zig-zag, armchair and chiral nanotubes4. As 
illustrated in Fig. 2.3, ‘zig-zag’ and ‘armchair’ are the only two cases of achiral 
nanotubes. Most nanotubes do not have these highly symmetric forms but have 
structures in which the hexagons are arranged helically around the tube axis. In 
general, these structures are known as chiral. 
 
.  
  (a)                    (b) 
Fig. 2.3 A schematic illustration of carbon nanotube structure of (a) armchair and (b) 
zig-zag4 
 
2.2.1.2 The Properties of Carbon Nanotubes 
 
The carbon-carbon covalent bond in graphite and carbon nanotubes is considered to 
be one of the strongest atomic bonds in nature. The mechanical properties of CNTs 
have been extensively studied, both experimentally and theoretically5-8. CNTs 
possess tensile moduli and strengths as high as 1 TPa and 150 GPa respectively. This 
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is an order of magnitude stronger than high strength carbon fibres. Their density can 
be as low as 1.3 gcm-3, which is lower than commercial carbon fibres at 1.8-1.9 
gcm-3. CNTs are thermally stable at up to 2800 oC in a vacuum. Their thermal 
conductivity is about twice as high as that of diamonds. Their 
electric-current-carrying capacity is 1000 times higher than that of copper wires4.  
 
Since the first CNTs and polymer composites were made in 19949, large amounts of 
work have been done on Polymer/CNT composites. Incorporating nanotubes into 
plastics can potentially provide structural materials with a dramatic increase in both 
stiffness and strength. Extensive studies have been carried out producing strong 
Polymer/CNT composites11-13. The effective use of CNTs as reinforcements still 
presents some major difficulties. The key challenge still remains in breaking down 
bundles of aggregated CNTs and reaching a fine dispersion in the selected polymer 
matrix. Much work needs to be done to optimise the conditions required for the 
potential dispersion of nanotubes as well as a good interfacial interaction12. 
 
2.2.2 Nanoclays  
 
Clay is a natural, earthy, fine-grained material and is the main constituent of the 
sedimentary rocks in marine sediments and in soils. Clay minerals belong to the 
family of phyllosilicates (or layered silicate) and have particles less than 2 µm in size 
as stated in ISO 1468814. There are three main groups of clays: kaolinite, 
montmorillonite-smectite and illite, and most clays are a mixture of these different 
types.  
 
In this work, sepiolite was chosen as the nanofiller. Sepiolite is a needle-like shaped 
nanoclay composed with elemental particles of lengths of 0.2-4 μm, widths of 10-30 
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nm and thicknesses of 5-10 nm. Sepiolite can have a surface area as high as 200-300 
m2g-1 and normally it is found stuck together as bundles of fibres which can form 
micro-agglomerates (Fig. 2.4a). Sepiolite is a hydrous magnesium silicate with 
[Si12O30Mg8(OH)4(H2O)4·8H2O] as the unit cell formula. The structure of sepiolite 
can be described as consisting of narrow strips which are formed by two sheets of 
tetrahedral silica units bonded to a central sheet of magnesium atoms. The strips link 
to each other by an inversion of the direction of the apical O of SiO4 tetrahedrons 
(Fig. 2.4b). Therefore, rectangular channels occur in the longitudinal direction of the 
strips14.  
 
Sepiolite provides a pseudoplastic and thixotropic behaviour which make it a 
valuable material in multiple applications to improve the processability, application 
or handling of the final product. Sepiolite has recently gained increasing attention as 
a reinforcement for polymeric matrices15,16. Montmorillonite is the most popular clay 
used for polymer nanocomposites. Compared with montmorillonite, the morphology 
of sepiolite provides a lower specific surface area and smaller contact surface 
between the nanoclay fibres. Therefore, polymer chains have a better chance not only 
of interacting with the external surface of the sepiolite, but also of penetrating into 
the structure, which facilitates a more even dispersion of the clays in the polymer 
matrix. Sepiolite has been successfully used to reinforce different polymers, such as 
poly (hydroxyethyl acrylate)15, chitosan17, epoxy16, etc.  
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(a) 
          
(b) 
Fig. 2.4 The structure of sepiolite fibre 
 
2.3 Polymer Nanocomposites 
 
For decades we have been dealing with polymer microcomposites, where the length 
scale of the fillers is in micrometres. In the case of polymer nanocomposites, 
nano-fillers, being additives of nanometre scale, are dispersed in a polymer matrix, 
offering multifunctional, high-performance polymer characteristics beyond those 
possessed by traditional filled polymeric materials. Improvements in physical and 
mechanical properties have been well documented in the literature4,10,18. Apart from 
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mechanical enhancements, the value of polymer nanocomposites comes from 
providing value-added properties not present in the polymer matrix, without 
sacrificing the inherent processability and mechanical properties of the matrix. The 
multifunctional features consist of improved thermal, fire, and moisture resistance, 
decreased permeability, charge dissipation, and chemical resistance12,15,18. 
 
The properties of nanocomposites can be greatly affected by the dispersion of the 
nanofillers in the polymer matrix19. Generally, the better the dispersion, the better the 
properties of the final nanocomposites. However, nanofillers are, in essence, 
agglomerates due to their high surface energy, and it is very difficult to disperse them 
in most polymers. The achievement of well-dispersed sepiolites or carbon nanotubes 
in polymer matrices is the most investigated research topic worldwide10,18,19. 
 
2.3.1 Polymer/CNT Nanocomposites 
 
Much effort has been expended in order to achieve good CNT dispersion and 
efficient stress transfer from the matrix to the tubes. Because of Van der Waals forces 
between individual CNTs, they tend to form bundles. The de-agglomeration of CNTs 
is necessary for dispersing individual nanotubes before mixing them with the 
polymer matrix.  
 
The ultrasonication process is the most common method, but severe sonication may 
make the tubes shorter20. Milling and grinding is considered to be a cheap and fast 
method for industrial processes although it is the most destructive method for CNTs21. 
Non-covalent functionalizations, such as surfactants, are often utilised to overcome 
carbon nanotube entanglement resulting from Van der Waals forces22. Covalent 
functionalization of CNTs helps to break up the CNT bundles and improves the 
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polymer/CNT interface adhesion23. Polymer wrapping has been proposed as an 
alternative method to achieve a good dispersion of the carbon nanotubes without 
destroying their electrical properties24. Dissociated CNTs were produced by grafting 
polymer chains directly onto the CNTs to achieve a homogeneous polymer coating 
on the CNT surface24-26. Enhanced dispersion and improved properties, compared 
with the direct incorporation of CNTs in polymer melts, has been reported for 
high-density polyethylene coated MWNTs in thermoplastic matrices such as 
ethylene-vinyl acetate, polycarbonate, polyamide and polypropylene (PP)24-29. Fig. 
2.5 illustrates four common types of functionalization of CNTs. 
 
 
 
Fig. 2.5 The functionalization of carbon nanotubes (1) oxidation (2) polymer grafted 
(3) surfactant-assisted and (4) polymer wrapped29 
 
2.3.2 Polymer/Clay Nanocomposites 
 
There are two ways to modify the surface of hydrophilic clays in order to improve 
their dispersion in the polymer matrix. The first one is to modify the surface with 
cationic surfactants to make the silicate surface organophilic via ion exchange 
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reactions30,31. The second method is based on grafting polymeric molecules through 
covalent bonding to the hydroxyl groups existing on the particles. However, for 
polyolefin polymers such as PP and PE, they are non-polar and incompatible with 
silicate surfaces even after modifying them with non-polar long alkyl groups. 
Therefore, a compatibilizer is needed to facilitate the interaction between the 
polymer and the clays32,33. Compatibilizers are usually polar functional oligomers 
providing both a hydrophobic part (which can be easily mixed with a polymer) and a 
hydrophilic part (which is compatible with clay). Maleic anhydride grafted 
polypropylene (PP-g-MA) is a commonly used compatibilizer to aid the dispersion of 
clay. 
 
 
Fig. 2.6 A possible morphology from the interaction of clays and polymer 
 
Depending on the degree of intercalation of matrix polymer chains into the galleries 
of the clays, intercalated or exfoliated nanocomposites can be obtained, and huge 
amounts of surface area can be created between the matrix polymer and the clay in 
the nanocomposites (Fig. 2.6).  Intercalation results from a limited insertion of 
polymer chains into the interlayer region and an interlayer expansion. In contrast, 
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extensive polymer penetration and delamination of clay crystallites leads to 
exfoliated nanocomposites, in which the nanometer-thick silicate platelets are 
homogeneously dispersed throughout the whole polymer matrix. Exfoliated 
nanocomposites usually provide the best property enhancement due to the large 
aspect ratio and surface area of the clay34. 
 
2.4 Processing Methods for Polymer Nanocomposites 
 
2.4.1 Traditional Processing Methods 
 
Nanocomposites can be prepared by different methods such as solution intercalation, 
in-situ polymerisation or melt compounding. 
 
Solution intercalation has been known for over a century and has proved to be one of 
the most successful methods for incorporating nanofillers into polymers. 
Nanocomposites with water-soluble polymers such as poly(ethylene oxide) and 
poly(vinyl alcohol)35,36 and organic solvent-soluble polymers such as HDPE37, have 
been successfully prepared via this method. However, their application on an 
industrial scale is still hindered by two major problems:  
 
1. The involvement of large quantities of aqueous/organic solvent 
2. A limited number of solvent/polymer pairs available for polymer dissolution  
 
In-situ polymerisation has been intensively investigated in recent years. The 
advantage of this process is that the polymer chain can be grafted onto the nanofillers 
on a molecular scale. This gives excellent dispersion and the potential for good 
interfacial strength between the nanofillers and the polymer matrix. A relatively good 
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dispersion can be maintained even with high nanotube loading in the matrix. 
Successful investigations have been reported in the literature from different 
groups38,39. The uniform dispersions of CNTs or clays were obtained and improved 
properties were observed. However, the molecular weight of the polymer is often 
significantly lower with a wide distribution by comparison with other methods. 
 
Melt compounding is the most common method used to process thermoplastic 
polymer nanocomposites because it is a cost-effective technology for 
polyolefin-based systems and is compatible with current industrial practices, such as 
extrusion, injection moulding, etc40. However, melt compounding, especially in the 
case of polyolefin matrices, is generally less effective at dispersing nanofillers such 
as CNTs and clays, and is limited to low nanofiller loadings due to the high viscosity 
of the composite systems caused by the addition of nanofillers40. Moreover, the high 
shear rates and high temperatures utilised can also cause thermal instability of the 
molten polymers41. One approach to promote compatibilization includes the use of 
polymer-coated nanofillers instead of pristine CNTs or clays into polymer melts. 
Alternatively, one can use the masterbatch process, where a pre-mixed highly loaded 
nanofiller composite is diluted with a fresh polymer melt42.  
 
2.4.2 The Supercritical Fluid Technique 
 
In recent years, supercritical technology, especially supercritical carbon dioxide 
(scCO2), has been widely applied in polymer processing. A supercritical fluid is 
defined as “any substance, the temperature and pressure of which are higher than 
their critical values, and which has a density close to, or higher than, its critical 
density” 43. Fig. 2.7 shows a schematic representation of the density and organization 
of molecules of a pure fluid in solid state, gas state, liquid state and the supercritical 
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domain. No phase separation occurs for any substance at pressures or temperatures 
above its critical values. In other words, the critical point represents the highest 
temperature and pressure at which gas and liquid can coexist in equilibrium.  
 
 
Fig. 2.7 A schematic representation of the microscopic behaviour of a pure fluid in 
the P-T plane phase diagram44 
 
Supercritical fluids are unique solvents with a wide range of interesting properties. 
Supercritical fluids have high diffusivities, similar to gas which allows them to effuse 
through solids, while also having liquid-like densities that allow them to act as 
effective solvents for many compounds. In addition, small changes in pressure and 
temperature greatly affect the density of a supercritical fluid and therefore many 
properties of SCF can be ‘fine-tuned’. The unique properties of supercritical fluids 
allow them to be widely exploited in the materials processing. The most promising 
developments are the processing of fine powders, core-shell particles, the processing 
and/or impregnation of aerogels, surface modifications and the processing of 
polymers44. 
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2.4.2.1 Supercritical Carbon Dioxide 
 
Among all the supercritical fluids, the use of supercritical carbon dioxide (scCO2) is 
the most desirable for polymer processing because of its environmental compatibility 
as well as the following properties: 
 
z CO2 has relatively easily accessible critical points of 31.06 °C and 1070 psi (7.38 
MPa) 45. 
z The density of scCO2 is easily tunable (Fig. 2.8). Therefore, the solvent strength 
and processes can be easily controlled.  
z CO2 is non-combustible and non-toxic in contrast to most of the organic solvents 
suitable for supercritical applications.  
z It is also easily available because it occurs naturally as well as being the 
by-product of many industrial processes; therefore CO2 is relatively inexpensive.  
z As CO2 is a gas at ambient temperatures and pressures it can be easily removed, 
leaving no solvent residues in the processed material46. 
 
 
Fig. 2.8 The density of CO2 as a function of pressure for a range of temperatures 
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ScCO2 has found widespread application in industrial processes, including the 
extraction of metals or organic material, the decaffeination of green coffee beans, dry 
cleaning and de-greasing, nano and micro particle formation, impregnation and 
dyeing, the processing and synthesis of polymers and composites, tissue engineering 
scaffolds, drug delivery, etc47-49. The important fields most relevant to this thesis are 
in the scCO2 processing of polymers and composites which will be discussed in 
greater detail below. 
 
ScCO2 processing, as one of the new and cleaner processing methods for polymer 
nanocomposites, has recently received increasing attention. The solubility of 
polymers in scCO2 is poor for many high molecular weight polymers. Table 2.1 
gives a representative sample of the available literature data for the solubility of CO2 
in a variety of polymers. The low solubility is a result of the lower density of scCO2 
and the weak interaction between the CO2 molecules and the non-polar groups of 
many polymers44. However, even for polymers which are not soluble in scCO2, the 
CO2 is still able to permeate resulting in substantial and sometimes dramatic changes 
in the properties of these polymers. The permeation of scCO2 into a polymer causes it 
to swell. Aided by their zero surface tension, the addition of scCO2 into the polymer 
phase gives the chains a greater mobility. The CO2 molecules act as lubricants, which 
reduces the chain-chain interactions as it increases the inter-chain distance and free 
volume of the polymer. This is called plasticization. The physical properties of the 
polymer are changed dramatically, including the depression of the glass transition 
temperature (Tg), the lowering of interfacial tension and a reduction of the viscosity 
of the polymer melt. ScCO2 may increase the crystallinity of the polymers because 
the polymer chains are given more freedom to align themselves into a more 
favourable order.  
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Table 2.1 The solubility of CO2 in polymers50 
Polymer Methoda Pressure  
[atm] 
Temp.  
[°C] 
Solubility 
poly(methyl methacrylate) GM-M 50 65 46 SCC/cm3 
 GM-D 204 70 10.5 wt.% 
polystyrene GM-M 13.2 25 14.5 SCC/cm3 
high-impact polystyrene GM-D 204 70 0.5 wt.% 
polycarbonate GM-M 13.2 25 24 SCC/cm3 
 GM-D 68 25 13 g/100g 
poly(ethylene terephthalate) GM-D 136 40 1.5 wt.% 
poly(vinyl chloride) GM-D 68 25 8 g/100g 
 GM-D 136 40 0.1 wt.% 
poly(vinyl acetate) GM-D 54.4 25 29 g/100g 
low density polyethylene GM-D 68 40 0.2 wt.% 
high density polyethylene GM-D 68 40 0.1 wt.% 
polypropylene GM-D 68 40 0.1 wt.% 
 GM-D 204 25 0.1 wt.% 
 BM 73 160 1.59 g/100g 
 BM 61.2 200 1.09 g/100g 
Nylon 66 GM-D 68 40 1.8 wt.% 
polyurethane BM 136 40 2.2 wt.% 
Teflon GM-D 68 40 0.0 wt.% 
aMethod: GM-M, gravimetric method (microbalance); GM-D, gravimetric method 
(desorption); BM, barometric method. Units: SCC/cm3, cm3(STP)/cm3 of polymer; 
g/100g, g of CO2/100g of polymer.  
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A wide range of opportunities have opened up for scCO2 that have an impact on the 
plastics industry50. These include usages for extraction, foaming and impregnation. 
Extraction occurs merely by removing the soluble extractant material, such as any 
unreacted monomer, while leaving the insoluble substrate. Foaming occurs when 
rapid decompression forms gaseous CO2 inside the polymer, leaving the polymer in 
the form of a porous (micro) material. This is very important in supporting the 
growth of blood vessels and collagen fibres in the matrix of biodegradable polymers 
or when the final product is intended to be used as a catalyst. As for impregnation, 
CO2 can act as a transport medium facilitating the diffusion of monomers, initiators 
and molecules to impregnate a polymer, while the CO2 can be cleanly removed 
afterwards. A better dispersion of the molecules has been provided within the 
polymer matrix. Substances impregnated into polymers have included dyes, 
fragrances, drugs for controlled release, anti-microbial and anti-fungal agents, and 
nanoparticles51. 
 
2.4.2.2 The Influence of ScCO2 on the Tg of Polymers 
 
Tg is the critical temperature that separates the glassy and rubbery behaviours of the 
polymers52. When a polymer at a temperature below its Tg, it is hard and brittle and 
its molecular chains are essentially frozen. If it is at a temperature above its Tg, its 
molecular chains can slide past each other, allowing it to be soft or rubbery.  
 
The introduction of scCO2 causes the plasticization of the polymer, which will 
increase the inter-chain distance and allow the chains to move past each other at 
lower temperature, hence decrease Tg53. The glass transition is a transition which 
happens to the amorphous phase of polymers. Therefore, for semi-crystalline 
polymers, the decrease of Tg. from the scCO2 is less significant compared with 
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amorphous polymers. Condo et al.54 has proposed a thermodynamic model of Tg 
behaviour versus CO2 solubility in the polymer. (Fig.2.9) According to Fig. 2.9, a 
higher CO2 sorption is needed to achieve a further decrease of Tg This near-linear 
prediction of the model has been backed up experimentally by many authors54-58. 
Table 2.2 lists the Tg depression of common polymers under CO2.  
 
Fig.2.9 Tg behaviour as a function of solubility (weight fraction units) of the 
compressed fluid in the polymer54 
 
Table 2.2 Tg depression of Polymers under CO250 
Polymer 
Pressure range 
investigated 
Tg depression -dTg/dP 
(°C/atm) 
poly(methyl methacrylate) 0-37 atm 1.2 
polystyrene 0-60 atm 1.08 
poly(vinyl chloride) 0-42 atm 1.45 
polycarbonate 0-56 atm 0.73 
poly(ethylene terephthalate) 0-20 atm 1.1 
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2.4.2.3 The Influence of ScCO2 on the Tm of Polymers 
 
The reduction of Tg by plasticization has been well established in the literature, while 
the influence of scCO2 on the melting temperature of semicrystalline polymers has 
interested many researchers. Handa et al.59 reported at 72 bar of CO2, the Tm of 
syndiotactic PS (270 °C) is lowered by about 12 °C. Varma-Nair et al.60 reported that 
Tm(onset) of isotactic polypropylene decreased from 147 °C at ambient pressure to ca. 
141 °C at 650 psi. As shown in the paper of Garcia-Leiner et al.61, HDPE can be 
continuously processed at temperatures below its melting point (127 °C) when CO2 
is introduced into the system. In semicrystalline polymers, the solubility of CO2 
occurs predominantly in amorphous regions. Varma-Nair et al. suggested that CO2 
absorbed in the amorphous regions will dilate the overall polymer matrix, which will 
lead to a lowering of the energy barriers. Some authors relate the decrease in Tm to an 
increase in the specific surface free energy caused by the dissolved CO2. The 
decrease in Tm benefits the moulding process greatly, in terms of energy saving, since 
the process can be operated at a lower temperature.   
 
2.4.2.4 The Influence of ScCO2 on the Crystallization of Polymers 
 
The effect of CO2 on the crystallization of a polymer is related to the temperature of 
maximum crystallization rate (Tmax). The crystallization rate changes with 
temperature and reaches its maximum at Tmax, which is close to the mean of Tg and 
the equilibrium melt temperature Tm0: Tmax ≈ (Tg+Tm0)/2. Above Tmax the overall 
crystallization rate is controlled by the nucleation rate, and the temperature region 
between Tmax and Tm0 is called the nucleation-controlled region. Below Tmax the 
overall rate is controlled by the crystal-growth rate. Fig. 2.10 shows the temperature 
dependence of the crystallization rate in the presence of CO2 and atmospheric air. 
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The dissolved CO2 will depress Tm0, and hence reduce Tmax to T’max. This means that 
the dissolved CO2 accelerates the crystallization rate of an isothermally crystallized 
semicrystalline polymer within the crystallization growth region and reduces the rate 
within the nucleation controlled region62.  
 
 
Fig. 2.10 The temperature dependence of the crystallization rate in the presence of 
CO2 and atmospheric air 
 
2.4.2.5 Polymer Nanocomposite Processing in ScCO2 
 
The effective dispersion of the fillers in the polymer matrix and the improvement of 
polymer-filler interactions are two key challenges in the field of polymer 
nanocomposites. The development of polymer processing technologies in scCO2 has 
enabled the synthesis of very complex polymer nanocomposites. ScCO2 can be used 
as the reaction medium allowing a homogeneous dispersion of the monomer, the 
initiator and the subsequent polymerisation under lower viscosity63. Green et al.64 
developed a poly(methyl methacrylate)/silicate nanocomposite in scCO2 exhibiting a 
significant improvement in physical properties. Poly(methyl methacrylate)/clay and 
polystyrene/clay have been produced via in-situ polymerisation with scCO2 acting as 
both a plasticizer for the polymer matrix and a carrier of the monomer63,65. Studies in 
Tmax T’max 
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PP have indicated improvements in the dispersion of nanofillers in the matrix via 
melt compounding in scCO266. 
 
2.5 Polypropylene Nanocomposites 
 
PP underwent a dramatic growth in production and use throughout the latter half of 
the 20th century67. PP is a thermoplastic polymer of the chemical designation C3H6. 
The main types of PP produced are isotactic PP and syndiotactic PP (Fig. 2.11). The 
position of the large methyl side group determines the tacticity of the PP molecule, 
which affects the ability of the molecules to crystallize. In isotactic PP, all the methyl 
groups are on the same side of the polymer chain, which allows a high degree of 
crystallisation. In contrast, atactic PP does not have the methyl groups on the same 
side of the polymer chain, which directly makes it non-crystallizable61. PP has been 
used in a wide variety of applications including packaging, fibres, textiles, stationary, 
pastic parts and reusable containers, automotive components, etc68.  
 
 
Fig. 2.11 Polypropylene (a) Isotactic and (b) syndiotactic 
 
Because of PP’s good balance between properties and cost and its wide usage in 
industry, PP nanocomposites have been extensively studied in recent years28,40,69,70. 
Due to the lack of polar groups in PP, many efforts have been attempted to improve 
the dispersion of inorganic fillers such as clay and CNTs into a PP matrix for the 
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preparation of effective PP nanocomposites and enhanced mechanical properties. 
Andrews et al.40 fabricated PP/MWNT composites by a shear mixer and found a 
modulus increase from 1.0 GPa to 2.4 GPa with a relatively high nanotube content of 
12.5 wt.%. However, this was at the expense of a reduction in yield stress from 30 
MPa to 18 MPa. Deng et al.28 investigated the effects of a high density polyethylene 
(HDPE) coating onto MWNTs on the mechanical properties of PP/MWNT 
composites produced by melt compounding. A property increase from 1.42 GPa to 
1.79 GPa for Young’s modulus and from 34.5 MPa to 37.9 MPa for tensile strength, 
was achieved at relatively low loadings (0.5 wt.%) of coated MWNTs. Liu and Wu70  
reported the preparation of PP/montmorillonite nanocomposites with the aid of a 
compatibiliser (maleic anhydride). Although the mechanical properties were 
improved in all cases, the lack of polar groups in the PP macromolecules makes it 
difficult to obtain well exfoliated nanocomposites and is limited to low nanofiller 
loadings. Moreover, due to the high temperatures and high shear rates involved in the 
melt compounding method, many problems may occur including the thermal 
instability of PP and the reduction of filler length, etc. 
 
By treating the PP with CO2, PP will become plasticized. CO2 can be absorbed only 
in the amorphous phase of the material and not in the crystalline phase. Narma-Nair 
et al.60 have suggested that 1% CO2 could be dissolved in PP at 50 °C at 180 psi. 
Both decreases in Tm and Tc of PP in presence of CO2 have been reported in the 
literature60,71. It has also been reported that a decrease in weight for PP under some 
scCO2 conditions, which suggested the extraction of some agents, such as monomers, 
oligomers, additives, or plasticizers from the polymer during the process72. Little 
difference has been found with the scCO2 plasticized PP compared with untreated 
one in both yield strength and modulus73.  
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2.6 Effective Mechanical Properties of Fillers in Polymer Composites 
 
The reinforcing efficiency of fillers in the polymer matrices has been extensively 
studied since 1950s. One of most common models is the rule of mixtures, which 
enables the comparison of literature results by the calculation of the effective 
contribution of the fillers to the composite properties. For composites in which 
discontinuous fibres are not perfectly aligned, the Young’s modulus of the composite 
(Ec) can be written as74:           
 
( ) mfffLo EVEVE −+= 1ηη                      2-1 
 
where ηL is the length efficiency factor, ηo is the orientation factor, Em and Ef are the 
Young’s modulus of the matrix and the fibre respectively, and Vf is the volume 
fraction of the fibre. ηL can vary between 0 and 1. ηo is equal to 1 for fully aligned 
fibres, 3/8 for random (in-plane) 2D orientation and 1/5 for random 3D orientation. A 
similar equation can be formulated for the strength: 
 
                    σc = ηLηo Vf σf + (1-Vf ) σm                     2-2            
 
Therefore, equations 2-1 and 2-2 can be used to evaluate the effective mechanical 
properties of CNTs in the composites. In the calculation, ηo was chosen to be the 
random 3D orientation value of 1/5, ηL equals 1 for high fibre aspect ratios (1/d > 
100). The volume fractions were deduced from the weight fractions and densities of 
the materials. 
 
 
 
c 
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2.7 Objectives for Part 1 
 
The achievement of well dispersed nanofillers in the polymer matrix is one of the 
most essential topics in the processing of polymer nanocomposites, particularly in 
melt compounding processes. Considering the high viscosities, high temperatures 
and high shear stresses involved in common melt compounding processes, scCO2 
processing can be an interesting alternative to produce PP nanocomposites as it 
should overcome some of these issues. The plasticization of scCO2 could reduce the 
PP viscosity, decrease the Tm of the PP, and hence increase the processablity of 
nanocomposites and improve the dispersion of nanofillers.  
 
The main objectives of this part are: 
 
1. To prepare PP/MWNT and PP/sepiolite nanocomposites using scCO2 assisted 
processing 
2. To study the properties of nanocomposites obtained using scCO2 processing by 
comparison with those of traditional melt compounded samples and to 
investigate the potential benefits of using scCO2 
3. To analyze the effective properties of the nanofillers in the nanocomposites 
using a simple micromechanical model 
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Chapter 3 
 
Polymer/Clay Nanocomposites using ScCO2 
Assisted Mixing 
 
 
 
 
3.1 Introduction  
 
 
In this research, scCO2 was used to prepare PP/sepiolite nanocomposites with and 
without the presence of PP-g-MA as a compatibilizer. Bilotti et al.1 previously 
reported the preparation of PP/sepiolite nanocomposites using the traditional melt 
compounding method. The benefits of performing this process with scCO2 are 
investigated in this study. The morphologies of various nanocomposites were 
identified, and the thermal properties were investigated. In addition, as PP is a 
semicrystalline polymer, its crystalline structure and morphology were also studied, 
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as these may be greatly affected by the interaction of the polymer with the clay as 
well as the processing conditions2. 
 
3.2 Experimental  
 
3.2.1 Materials and Equipments 
 
The PP used was Moplen® HP500H from Basell. Moplen® HP500H, which has a 
softening temperature of 151 °C (A50 (50 °C/h 10 N)), density of 0.9 g/cm3 at 20 °C 
and a melt flow rate (MFR) of 1.8 g/10min (230 °C/2.16kg). The clay used was 
Sepiolite Pangel® supplied by Tolsa (Spain). Sepiolite Pangel® has a bulk density of 
~ 60 g/L. All materials were used as obtained. The average length of an individual 
sepiolite nano-fibre is 1-2 μm and its diameter is in the range of 20-30 nm. The 
compatibilizer used was PP-g-MA having a commercial grade of VINBOND® P 
series (VB100; 1 % grafted MA), and was purchased from Vin Enterprise Ltd. A 
liquid withdrawal CO2 cylinder at 725 psi pressure was supplied by BOC gases. A 
custom-built stirred high-pressure autoclave with paddle type stirrer was used to 
prepare the nanocomposites. A Rondol laboratory bench-top hot-press was used to 
produce the dumbbell-shaped specimens. 
 
3.2.2 Processing of PP/clay Nanocomposites 
 
A custom-built high-pressure autoclave made from stainless steel was used with an 
ISCO pump. Fig. 3.1 shows the system diagram. Abbreviations in the Fig. 3.1 are 
explained as below: PR: Pressure Regulator, EP: Electronic Pressure Gauge 
(Transducer), T: TAP, TC: Temperature Controller, PG: Pressure Gauge, F: Filter, and 
BPR: Back Pressure Regulator.  
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Fig. 3.1 System
 diagram
 
 
Chapter 3. Polymer/Clay Nanocomposites using ScCO2 
 65
PP and sepiolite with and without PP-g-MA were loaded in the autoclave. The 
amount of PP-g-MA in the nanocomposites was equivalent to the amount of sepiolite 
(1:1 weight ratio). CO2 was pumped into the autoclave via an Isco model 260D 
syringe pump after being chilled to -6 °C. The autoclave was heated up and held at 
2175 psi and 200 °C under stirring using a pitched bladed turbine impeller for 30 min. 
The stirring speed was set at maximum power. After mixing, the autoclave was 
cooled in water to room temperature, and CO2 was vented slowly. Nanocomposites 
having clay contents of 1 wt.%, 2.5 wt.%, 5 wt.% and 10 wt.% were obtained by 
selecting different weight ratios between the PP and the sepiolite. The bulk materials 
obtained from the autoclave were frozen in liquid nitrogen and then broken into 
pieces, which were subsequently used for hot pressing into dumbbell-shaped 
specimens according to ASTM D-638 at 200 oC under 5800 psi for 5 min. The 
samples were cooled down to room temperature using the water cooling system of 
the hot-press. 
 
3.2.3 Characterization 
 
Scanning Electron Microscopy (SEM) was used to investigate the morphological 
characteristics using a JEOL 6300TM (accelerating voltage 10 kV) in the normal 
secondary electron imaging mode. Prior to the examination, the samples were 
freeze-fractured in liquid nitrogen and sputter coated with a thin layer of gold by 
using a sputter coater (Emitech K550). Transmission Electron Microscopy (TEM) 
was carried out using a JEOL JEM 2010 TEM. The ultra-thin samples were prepared 
by an ultra microtome.  
 
DSC was performed using a Mettler Toledo DSC 822e. Samples of about 5mg were 
heated from 30 to 250 oC at a heating rate of 10 oC/min in dry nitrogen and held for 
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10 min to erase any thermal history, and then cooled to -50 ºC using the same scan 
rate of 10 ºC/min.  
 
X-ray diffraction (XRD) data were recorded for thin film samples using a Siemens 
D5000 Diffractometer, where the X-ray beam was Cu-K radiation (kα1 = 1.5406 Å) 
and the radiation operated at 40 kV. Data were collected over the 2θ range 5-30 º 
with a step size of 0.01 º and a step time of 1 sec.  
 
Tensile tests were performed using an Instron 5584 tensile testing machine, equipped 
with a 1 kN load cell, standard grips and Merlin data acquisition software. The tests 
were conducted according to the ASTM D-638 standard. Crosshead displacements of 
5 mm.min-1 and 10 mm.min-1 were used for measuring Young’s modulus and tensile 
stress, respectively. The Modulus of each specimen was calculated as the gradient of 
the stress vs. strain curve between 0.05 % and 0.2 % strain. The values presented for 
all the properties are the average of 5 repetitions of each test. 
 
3.3 Results and Discussion  
 
Fig. 3.2 shows the morphology of the nanocomposites produced by scCO2. A porous 
foamed structure is formed. The increase of the clay content results in the smaller 
size of pores. This porous structure will be removed during the hot pressing process 
performed afterwards, thus dense samples are produced.  
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Fig. 3.2 SEM images of scCO2 processed nanocomposites before hot press (a) scCO2 
PP+1 wt.% sepiolite (b) scCO2 PP+2.5 wt.% sepiolite and(c) scCO2 PP+5 wt.% 
sepiolite showing that the porous structures were formed   
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The SEM images of the samples after hot pressing are presented in Fig. 3.3. The 
bright spots represent sepiolite in the images. Under higher magnification, it is clear 
to see that the sepiolite fibres sticking out the fracture surface of polymer (Fig. 3.3b).   
 
 
(a) 
 
(b) 
Fig. 3.3 SEM images of freeze-fractured samples for scCO2 PP+2.5 wt.% 
PP-g-MA+2.5 wt.% sepiolite (a) low magnification (b) high magnification  
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The comparison between images of the scCO2 processed nanocomposites and 
traditional melt compounded ones, which are from the work by Bilotti et al.1, is 
shown in Fig. 3.4. The large aggregates of sepiolite fibres, as observed in melt 
compounded PP nanocomposite (see encircled regions in Fig. 3.4(a) and (b)), are not 
observed in the scCO2 PP nanocomposites (Fig. 3.4(c) and (d)). This confirms the 
better dispersion of clay with scCO2 assisted mixing suggested by other authors3. 
Especially, for the scCO2 nanocomposites prepared without PP-g-MA (Fig. 3.4(c)), 
the dispersion of sepiolite in the PP matrix has improved significantly and is as good 
as the one using PP-g-MA as a compatibilizer in the scCO2 assisted mixing (Fig. 
3.4(d)). This indicates that PP-g-MA is not necessary to achieve a good dispersion in 
scCO2 assisted processing. This is of particular relevance because the role of 
compatibilizers, such as PP-g-MA, is generally regarded as essential for the creation 
of well dispersed nanoclay composites using traditional melt compounding methods1. 
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Fig. 3.4 SEM images of freeze-fractured samples for (a) melt compounded PP+2.5 
wt.% sepiolite1 (b) melt compounded PP+2.5 wt.% PP-g-MA+2.5 wt.% sepiolite1 (c) 
scCO2 PP+2.5 wt.% sepiolite and (d) scCO2 PP+2.5 wt.% PP-g-MA+2.5 wt.% 
sepiolite 
 
The TEM image (Fig. 3.5) of a scCO2 PP nanocomposite is compared with the 
original sepiolite suspended in a water solution and also a melt compounded PP 
nanocomposite. A higher magnification was used for identifying the sepiolite in the 
nanocomposites because the sepiolite was widely dispersed inside the polymer and 
broken into much shorter length so that the lower magnification failed to present 
them clearly. Especially for melt compounded PP/sepiolite nanocomposite, on 
average of 10 pictures taken under TEM, the clearest picture we could get is Fig. 
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3.5(b)1. They reported significant reduction in sepiolite length due to the 
compounding process, while the fibre bundles and aggregates could not be 
effectively broken down (Fig. 3.5(b)). In this work, sepiolite needles appear to be 
separated from each other in scCO2 PP nanocomposites (Fig. 3.5(c)). Although some 
reduction in fibre length seems to have occurred, a length of about 400-500 nm was 
still preserved after the scCO2 assisted mixing process, which is much longer than 
that of the sepiolite fibres in the melt-compounded samples (see Fig. 3.5(b)). This 
indicates the greater efficiency of scCO2 to prevent breakage and aggregation of 
sepiolite, which should lead to a higher reinforcing efficiency of the sepiolite.    
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Fig. 3.5 TEM images of (a) original sepiolite in aqueous solution1 (b) melt 
compounded PP/sepiolite nanocomposite1 and (c) scCO2 PP/sepiolite nanocomposite 
showing less fibre length reduction for scCO2 processed sample  
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Fig. 3.6 Young’s modulus of PP nanocomposites prepared using different methods 
and clay contents 
 
The values of Young’s modulus of scCO2 PP nanocomposites with different clay 
content are presented in Fig. 3.6. For comparison, the results for melt compounded 
PP nanocomposites are also included1. The Young’s modulus of melt compounded PP 
nanocomposites (no compatibilizer) shows a reduction with the increase of the clay 
content. This corresponds to the aggregation of clay at higher loadings with the 
absence of the compatibilizer (Fig. 3.4a and Fig. 3.5b), hence the modulus is reduced. 
This is in contrast to the analogous material with a compatibilizer, which shows a 
68 % increase in modulus from 1 to 5 wt.% clay content. If one compares the two 
modulus plots for scCO2 PP nanocomposites with and without a compatibilizer (Fig. 
3.6), it can be seen that the modulus value for the plot with a compatibilizer remains 
roughly constant across the differing clay contents. In contrast, the plot without 
compatibilizer shows a steady increase in modulus (by up to 56 % for 5 wt.% 
sepiolite), suggesting that the compatibilizer has a negative effect on the modulus 
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(and indeed the yield stress; see discussion later). The increase of clay content 
compromises the ductile nature of the PP matrix. Yielding followed by drawing still 
occurred in the 1 wt.% sepiolite samples; while 2.5 wt.% and 5 wt.% sepiolite 
samples show brittle fractures at low strains (Fig. 3.7). The effects of scCO2 
processing on the mechanical properties of pure PP have been investigated in the past, 
and the research showed that little difference was made in both yield strength and 
modulus of PP4. The potential factors which would affect the mechanical properties 
of PP, such as changing in the degree of crystallinity, would be removed during the 
hot pressing procedure in the preparation of testing samples. The only remaining 
effect of scCO2 processing is the extraction of small agents, such as monomers, or 
oligomers from PP, which would lead to a decrease of the weight5. 
 
 
Fig. 3.7 Stress-strain curves of scCO2 PP/sepiolite nanocomposites with different 
clay contents  
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Fig. 3.8 Yield stress of PP nanocomposites prepared using different methods and clay 
contents 
 
Fig. 3.8 shows an increase in yield stress for scCO2 PP nanocomposites of up to 23 % 
for 5 wt.% sepiolite samples compared with pure PP and a significant improvement 
over those prepared using melt compounding was also observed, which confirms the 
good dispersion of the sepiolite in the PP matrix (Fig. 3.4c and d) and also the benefit 
of preserving the fibre length when using scCO2 assisted mixing (Fig. 3.5c). 
Moreover, scCO2 PP nanocomposites without the PP-g-MA compatibilizer, possess 
an even higher yield stress than those with the compatibilizer. The reasons for this 
are not immediately clear. However, because the compatibilizer may reduce the yield 
stress of scCO2 PP nanocomposites, it may have resulted in scCO2 forming 
interactions with the compatibilizer molecules, since scCO2 has been identified as a 
good solvent and carrier agent for maleic6. These interactions may disrupt the normal 
compatibilizer behaviour. In contrast, for the melt compounded samples, the 
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compatibilizer is more likely to be able to act at the polymer/clay interface. 
Furthermore, the interactions between scCO2 and the compatibilizer may also result 
in the compatibilizer being located unevenly in the PP phase by being trapped more 
around the micro-cells when CO2 is vented, which may induce the uneven dispersion 
of the clay. Hence, the addition of the compatibilizer in the scCO2 PP 
nanocomposites may not be acting effectively at the polymer/clay interface.  
 
Fig. 3.9 presents the DSC cooling curves of pure PP and scCO2 PP nanocomposites. 
The crystallization temperature (Tc) of the pure PP sample is 111 °C. However, for 
PP nanocomposites, it is observed that the crystallization temperature shifts to higher 
temperatures, which indicates that the sepiolite fibres act as nucleating agents for PP 
crystallization. This increase in crystallization temperature is dependent on the clay 
content, which suggests that higher loadings of sepiolite can provide higher 
nucleating efficiency. These results is corresponding well to the findings in the 
literature that both degree of crystallinity and crystallization rate are increased due to 
the nucleation effect of sepiolite7.  
 
Fig. 3.9 The DSC crystallisation peaks for typical scCO2 PP/sepiolite 
nanocomposites 
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The degree of crystallinity (Xc) is calculated from the melting heat (ΔHm) obtained 
from DSC measurement according to the following equation8: 
 
 
       
where ΔH0 = 209 J/g is the melting enthalpy of 100 % crystalline PP and fc is a factor 
that simply takes into account the excluded mass of inorganic that does not melt. For 
instance, fc is 0.99 for a 1 wt.% nanocomposite DSC data of the Tc and the Xc are 
presented in Table 3.1. The addition of clay has little influence on the Xc. All the 
samples with different clay content show very similar degree of crystallinity, which 
suggests that the increase in modulus and yield stress of PP nanocomposites were 
contributed mainly from the reinforcement of sepiolite fibres.   
 
Table 3.1 DSC measurement results 
Sample 
Sepiolite 
[wt.%] 
PP-g-MA 
[wt.%] 
Tc 
 [°C] 
Xc 
[%] 
ΔHm 
J/g 
PP 0 0 110.8 31.5 65.8 
PP/sepiolite 
 
 
1 0 115.6 31.0 65.4 
2.5 0 119.6 31.2 66.9 
5 0 123.8 29.1 64.0 
PP/PP-g-MA/sepiolite 
 
 
1 1 117.0 30.5 64.4 
2.5 2.5 120.5 29.4 63.0 
5 5 122.5 28.8 63.4 
 
iPP can crystallize in three crystalline modification: monoclinic (α), hexagonal (β), 
orthorhombic (γ)9. These phases can be examined by XRD. The XRD patterns for all 
3-1 
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the PP nanocomposites show peaks corresponding to PP α-phase at 2θ = 14, 17, 18.5, 
21.5, 21.9 and 25.4 ° for six major reflections: (110), (040), (130), (111), (041) and 
(060) plane, respectively (Fig. 3.10). No other reflections for other forms of PP 
crystallites were detected. This indicates that the addition of sepiolite does not affect 
the crystal modification of the final PP molecules. However, it should be noted that 
the relative intensity of the peaks for (040) increased considerably with the presence 
of sepiolite, taking the (110) peak as reference. Data of relative intensities are listed 
in Table 3.2. This phenomenon has also been noticed by other researchers1,10. A 
possible reason for this increase is that the addition of sepiolite promotes a 
preferential orientation of PP crystals growing with (040) planes parallel to the 
sepiolite surface and the b-axes perpendicular to it10,11.  
 
Table 3.2 Ratio of intensity between diffraction peaks of (040)α and (110)α in XRD 
patterns 
Sepiolite [wt.%] 0 1 2.5 5
PP/sepiolite 0.80 2.41 2.40 2.24
PP/PP-g-MA/sepiolite 0.80 1.40 3.00 2.71
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Fig. 3.10 XRD patterns of (a) PP/sepiolite and (b) PP/PP-g-MA/sepiolite 
nanocomposites 
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3.4 Conclusions 
 
PP/sepiolite nanocomposites with and without PP-g-MA as a compatibilizer were 
prepared using scCO2 assisted mixing and compared with those processed by a 
traditional melt compounding method. A relatively homogeneous dispersion of 
sepiolite was obtained throughout the PP matrix for the nanocomposites processed in 
scCO2 even without the aid of PP-g-MA as the compatibilizer. Well separated 
sepiolite fibres were observed from TEM images and the fibre length in the scCO2 
assisted mixing is retained better than in melt compounding. Consequently, 
mechanical properties of PP nanocomposites prepared in scCO2 were significantly 
improved, especially without the need of PP-g-MA. All these facts indicate that 
scCO2 can give significant benefits for preparing PP/sepiolite nanocomposites. 
Especially, the fact that PP-g-MA, which is normally used as a compatibilizer in melt 
compounding, is not needed for the processing of high quality PP nanocomposites 
using scCO2 is highly relevant from a technological and economical point of view. 
Similarly to other nanocomposite studies also in this study it was found that 
nanoclays can act as nucleating agents and increase the crystallization temperature of 
the PP matrix in nanocomposites. Moreover, the nanocomposites only contained PP 
α-phase crystallites with the clay inducing a preferred orientation for the PP. 
 
3.5 References 
 
1. Bilotti E, Fischer HR and Peijs T. Polymer Nanocomposites Based on Needle-Like 
Sepiolite Clays-Effect of Compatibilizers on Morphology, Crystallinity and Mechanical 
Properties. J. App. Polym. Sci. 2008, 2, 1116 
2. Pukanszky B, Mudra I and Staniek P. Relation of Crystalline Structure and Mechanical 
Properties of Nucleated Polypropylene. J. Vinyl. Addit. Technol. 1997, 1, 53 
 
Chapter 3. Polymer/Clay Nanocomposites using ScCO2 
 81
3. Garcia-Leiner M and Lesser AJ. Polymer Nanocomposites Prepared by Supercritical 
Carbon Dioxide-Assisted Polymer Processing. Polym. Prepr. 2004, 45, 520 
4. Shieh YT, Su Jh, Manivannan G, Lee PHC, Sawan HP and Spall WD. Interaction of 
Supercritical Carbon Dioxide with Polymers. I: Crystalline Polymers. J. Appl. Polym. Sci. 
1996, 59, 695 
5. Fleming GK and Koros WJ. Dilation of Polymers by Sorption of Carbon Dioxide at 
Elevated. Pressures. 1. Silicone Rubber and Unconditioned Polycarbonate. Macromol. 
1986, 19, 2285 
6. Galia A, Gregorio R, Spadaro G, Scialdone O and Filardo G. Grafting of Maleic Anhydride 
onto Isotactic Polypropylene in the Presence of Supercritical Carbon Dioxide as a Solvent 
and Swelling Fluid. Macromol. 2004, 12, 4580  
7. Acosta JL, Ojeda MC, Morales E, and Linares A. Morphological, Structural, and Interfacial 
Changes Produced in Composites on the Basis of Polypropylene and Surface-Treated 
Sepiolite with Organic-Acids .3. Isothermal and Nonisothermal Crystallization. J. Appl. 
Polym. Sci. 1986, 32, 4119 
8. Jang GS, Cho WJ and Ha CS. Crystallization Behavior of Polypropylene with or without 
Sodium Benzoate as a Nucleating Agent. J. Polym. Sci., Part B: Polym. Phys. 2001, 39, 
1001 
9. Bruckner S, Meille SV, Petraccone V and Pirozzi B. Polymorphism in Isotactic 
Polypropylene. Prog. Polym. Sci. 1991, 16, 361 
10. Ferrage E, Martin F, Boudet A, Petit S, Fourty G, Jouffret F, Micoud P, De Parseval P, Salvi 
S, Bourgerette C, Ferret J, Saint-Gerard Y, Buratto S and Fortune JP. Talc as Nucleating 
Agent of Polypropylene: Morphology Induced by Lamellar Particles Addition and Interface 
Mineral-matrix Modelization. J. Mater. Sci. 2002, 37, 1561 
11. Wang LH, and Sheng J. Preparation and Properties of Polypropylene/org-attapulgite 
Nanocomposites. Polym. 2005, 46, 6243 
 
Chapter 4. Polymer/CNT Nanocomposites using ScCO2 
82 
 
 
 
Chapter 4 
 
Polymer/CNT Nanocomposites using ScCO2 
Assisted Mixing 
 
 
 
 
4.1 Introduction 
 
In this chapter, the use of scCO2 to assist the preparation of PP/CNT nanocomposites 
and the potential benefits thereof are investigated. Two types of CNTs were used: 
pure MWNTs and 31.6 % MWNTs pre-dispersed in a HDPE coating (cMWNTs). 
The resulting morphology and thermal properties of the nanocomposites were 
studied using SEM, TEM, DSC and TGA. The dispersion, physical and mechanical 
properties of nanocomposites obtained using scCO2 processing were compared with 
those of traditional melt compounded samples. Micromechanical modelling was used 
to analyse the effective properties of the CNTs in the nanocomposites. The current 
study also addresses the effects of PP matrix modification by the CNTs and their 
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effects on the mechanical properties of the nanocomposites. 
 
4.2 Experimental 
 
4.2.1 Materials and Equipments 
 
The PP used was Moplen® HP500H from Basell (Melt Flow Index = 1.8 g/10 min). 
The pristine MWNT used was Nanocyl®-7000 from Nanocyl S.A. (Belgium), which 
is a thin MWNT produced via the catalytic chemical vapour deposition process, 
achieving a purity of 90 % carbon. Nanocyl®-9000 is an HDPE-coated MWNT 
(cMWNTs) which contains 31.6 % of nanotubes pre-dispersed in a polymer carrier 
using a proprietary technology1,2. All materials were used as received. A liquid 
withdrawal CO2 cylinder at 725 psi pressure was supplied by BOC Gases. A 
custom-built stirred high-pressure autoclave with a paddle type stirrer was used to 
prepare the nanocomposites. The system diagram is presented in Fig. 3.1. A Rondol 
laboratory bench-top hot-press was used to produce the dumbbell-shaped specimens. 
 
4.2.2 Processing of PP/MWNT Nanocomposites 
 
MWNTs (or cMWNTs) were directly added to the PP matrix in an autoclave to 
obtain a CNT concentration of 0.1 wt.%, 0.25 wt.%, 0.5 wt.% and 1.0 wt.%. CO2 
was pumped into the autoclave via an Isco model 260D syringe pump after being 
chilled to -6 oC. The autoclave was filled with liquid CO2 and held at 2175 psi and 
200 °C under stirring, using a pitched blade turbine impeller for 30 min. After mixing, 
the autoclave was cooled in water to room temperature, and then the CO2 was vented. 
In comparison, a masterbatch of 3.0 wt.% CNT content was prepared using scCO2 
assisted mixing under 2175 psi and 200 °C for 10 min before being diluted into 
Chapter 4. Polymer/CNT Nanocomposites using ScCO2 
84 
 
lower concentrations of 0.1 wt.%, 0.25 wt.%, 0.5 wt.% and 1.0 wt.% CNT using the 
same conditions as described above. The bulk materials obtained from the autoclave 
were frozen in liquid nitrogen and then broken into pieces, which were subsequently 
used for hot-pressing into dumbbell-shaped specimens according to ASTM D-638 at 
200 oC under 5800 psi for 5 min. The samples were cooled down to room 
temperature using the water cooling system of the hot-press. The nanocomposites 
along with their compositions, including those from Deng et al. work3, are listed in 
Table 4.1 for comparison. 
 
Table 4.1 The composition of PP/CNTs nanocomposites 
 
4.2.3 Characterization 
 
SEM was used to investigate the morphological characteristics using a JEOL 6300 
(accelerating voltage 10 kV) in the normal secondary electron imaging mode. Prior 
to the examination, samples were freeze-fractured in liquid nitrogen and sputter 
coated with a thin layer of gold. Transmission electron microscopy (TEM) was 
carried out using a JEOL JEM 2010. MWNTs were dispersed in ethanol using 
Sample CNT type Processing method 
scCO2PP/MWNT Nanocyl®-7000 scCO2 
scCO2.m PP/MWNT Nanocyl®-7000 scCO2; masterbatch 
scCO2PP/cMWNT Nanocyl®-9000 scCO2 
scCO2.mPP/cMWNT Nanocyl®-9000 scCO2,; masterbatch 
melt.mPP/MWNT3 Nanocyl®-7000 melt compounded; masterbatch 
melt.mPP/cMWNT3  Nanocyl®-9000 melt compounded; masterbatch 
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ultrasonication for 5 min and then drops of suspension were deposited onto a copper 
grid for TEM observation. 
 
DSC was performed using a Mettler Toledo DSC822e. Samples of about 5 mg were 
heated from -50 ºC to 200 ºC at a scan rate of 10 ºC/min and held for 10 min to erase 
any thermal history, and then cooled to -50 ºC using the same scan rate of 10 ºC/min. 
Thermogravimetric analysis (TGA) was carried out under nitrogen atmosphere in the 
temperature range of 20-1000 ºC by using a TA TGA Q500. The heating rate used 
was 20 ºC/min. 
 
XRD data were recorded with a Siemens Diffractometer D5000, where the X-ray 
beam was Ni-filtered CuKα (λ = 1.5405 Ǻ) and the radiation was operated at a rate 
of 40 kV with a filament current of 40 mA. Corresponding data were collected from 
5 to 30 ° with a step size of 0.01 º and a step time of 1 sec.  
 
Tensile tests were performed using an Instron 5566 machine, equipped with a 1 kN 
load cell, standard grips and Merlin data acquisition software. The tests were 
conducted according to the ASTM D-638 standard. The Young’s modulus of each 
specimen was calculated and the gradient of the stress vs. strain curve was measured 
between 0.05 % and 0.2 % strain. The values presented for all the properties are the 
average of 5 repetitions of each test. 
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4.3 Results and Discussion 
 
Fig. 4.1 shows the SEM images of the nanocomposites produced by scCO2. 
Nanotubes are observed as bright spots and with the increase of the nanotube content, 
more bright spots can be seen from the images. 
 
  
 
 
Fig. 4.1 SEM images of freeze-fractured samples of PP nanocomposites with  (a) 0.1 
wt.% scCO2.mPP/cMWNT (b) 0.5 wt.% scCO2.mPP/cMWNT 
(a) 
(b) 
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Fig. 4.2 SEM images of freeze-fractured samples of PP nanocomposites with 0.5 
wt.% MWNT loading (a) melt.mPP/MWNT3 (b) melt.mPP/cMWNT3 (c) 
scCO2PP/MWNT (d) scCO2 PP/cMWNT (e) scCO2.mPP/MWNT and (f) 
scCO2.mPP/cMWNT 
  
Fig. 4.2 compares the images of the scCO2 processed nanocomposites and traditional 
melt compounded ones. In the case of conventional melt compounding, better 
(c) (d) 
(a) (b) 
(e) (f) 
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dispersions of CNTs were observed for the HDPE coated MWNTs samples, owing to 
the de-aggregated state of the cMWNTs1. (Fig. 4.2a and 2b) However, in the case of 
scCO2 assisted mixing, large aggregates of cMWNTs were observed (Fig. 4.2d) and 
even when a masterbatch method was applied the cMWNTs were still not well 
dispersed (Fig. 4.2f). Interestingly, pristine MWNTs without HDPE coating provided 
a better and more homogeneous dispersion in the PP matrix (Fig. 4.2c). Similar 
improvements in dispersion, for scCO2 assisted mixing without the use of 
compatibilizers were also reported for nanoclays in PP matrices. A better dispersion 
of MWNTs was observed using the masterbatch method (Fig. 4.2e). 
 
 
Fig. 4.3 TEM images of (a) pristine MWNTs and (b) HDPE coated MWNTs 
    
The TEM images of MWNTs and cMWNTs, which are presented in Fig. 4.3 may 
help to explain why the dispersion of cMWNTs in the PP matrix was unsatisfactory 
in scCO2 assisted mixing. Pristine MWNTs could be dispersed into individual tubes 
on the grid with no large aggregates remaining (Fig. 4.3a). However, cMWNTs (Fig. 
4.3b) showed quite a different structure. The polymer coated MWNTs form large 
(a) (b) 
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agglomerates and although the HDPE coating helps to separate the individual 
nanotubes, the break up of these agglomerates still requires high shear forces. 
Therefore, cMWNTs can be dispersed well in conventional melt compounding 
processes in twin-screw extruders because of the high shear forces employed. 
However, a pitched blade turbine impeller, used in scCO2 assisted mixing, generates 
much lower shear forces, thus leading to poor dispersion of these agglomerates.  
 
 
Fig. 4.4 The Young’s modulus of PP nanocomposites as a function of MWNT loading, 
showing that a similar modulus is achieved for scCO2 processed nanocomposites 
with pristine MWNTs and melt-compounded nanocomposites with coated cMWNTs. 
Solid lines represent results of nanocomposites with pristine MWNTs, whereas 
dashed lines represent nanocomposites with coated cMWNTs 
   
The values of Young’s modulus of the nanocomposites with different MWNT 
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loadings are presented in Fig. 4.4. As a result of the de-aggregation of the MWNT 
bundles by the HDPE coating, the melt-compounded and masterbatch based 
PP/cMWNT composites show a continuous modulus increase up to 1.7 GPa from 
zero to 1.0 wt.% CNT loading3. Based on uncoated MWNTs, the same 
melt-compounded and masterbatch systems only displayed a Young’s modulus value 
of 1.5 GPa for 1.0 wt.% CNT loading, due to the poor dispersion of pristine MWNTs 
in the PP matrix3 (Fig. 4.2a) . Interestingly, scCO2 processed nanocomposites with 
pristine MWNTs showed an increase in Young’s modulus, which is as good as, or 
even better than, that of melt.m PP/cMWNT. However, cMWNTs showed the lowest 
reinforcing efficiency in the case of scCO2 processed nanocomposites. It is in the 
agreement with results from the SEM images that MWNT can achieve better 
dispersion than cMWNT in the scCO2 processing (Fig. 4.2c and e comparing with 
Fig. 4.2d and f). Furthermore, the use of masterbatch in the scCO2 assisted mixing 
method did not show improvements in terms of Young’s modulus, as shown for both 
scCO2.mPP/MWNT and scCO2.mPP/cMWNT composites. The reason may be the 
long processing times needed at these high temperature conditions causing a 
degradation of the PP matrix. 
 
Similarly, increases in yield stress were observed for all scCO2PP/MWNT samples, 
with a significant 6 % increase from zero to 0.1 wt.% CNT loading followed by 
roughly constant values across the rest of the CNT loading range up to 1 wt.% (Fig. 
4.5). The degree of reinforcement of pristine MWNTs is as good as for 
melt-compounded coated PP/cMWNT composites. PP/cMWNTs composites, 
showing poor nanofiller dispersion in the case of scCO2 assisted mixing, give lower 
yield stresses. Although the HDPE coating indeed helps the dispersion of cMWNTs 
in melt compounding processes, the HDPE coating could also act as a weak interface 
between the matrix and the CNTs, leading to a poor stress transfer, thereby 
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weakening the nanocomposites. This potential effect is however not found here. 
ScCO2 assisted mixing achieves a better dispersion of CNTs without the need for 
HDPE coating, therefore eliminating the potential drawbacks of HDPE coating, 
leading to greater thermal and mechanical reinforcing effects from the MWNTs. Also, 
the relatively low shear forces involved in scCO2 assisted mixing cause less nanotube 
breakage and damage (Fig. 4.3c). 
 
 
Fig. 4.5 The Yield stress of PP nanocomposites as a function of MWNT loading, 
showing that a similar yield stress is achieved for scCO2 processed nanocomposites 
with pristine MWNTs and for melt-compounded and masterbatch based 
nanocomposites with HDPE coated MWNTs. The solid lines represent the results of 
nanocomposites with pristine MWNTs, whereas the dashed lines represent those of 
the nanocomposites with coated cMWNT 
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From Fig. 4.6, strain at break was observed to decrease significantly with the CNT 
loading for all sets of samples which indicates that the increase of CNT loading 
compromises the ductile nature of the PP matrix. Not surprisingly, the strain values 
of scCO2PP/cMWNTs are the lowest among all due to its large aggregations of 
MWNTs in the nanocomposites which act as defects accelerating the final failure of 
the sample under stress. Furthermore, the increase in the crystallinity of PP by the 
addition of MWNTs, which will be discussed in the later text, has been suggested as 
one of factors causing the decrease of the strain at break4.  
 
 
Fig. 4.6 Strain curves of the nanocomposites prepared using different methods and 
MWNT loading 
 
To calculate the reinforcing efficiency of the CNTs in composites, as introduced in 
the Chapter 2, the rule of mixture is applied to quantify the effective Young’s 
modulus of the CNTs. For composites in which discontinuous fibres are not perfectly 
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aligned, the Young’s modulus of the composite (Ec) can be written as5:  
 
                   ( ) mfffLo EVEVE −+= 1ηη                     4-1 
 
where ηL is the length efficiency factor, ηo is the orientation factor, Em and Ef are the 
Young’s modulus of the matrix and the fibre respectively, and Vf is the volume 
fraction of the fibre. ηL can vary between 0 and 1. ηo is equal to 1 for fully aligned 
fibres, 3/8 for random (in-plane) 2D orientation and 1/5 for random 3D orientation. A 
similar equation can be formulated for the strength, where σm, σm and σf are the 
tensile strengths of the composites, matrix and fibre, respectively. 
 
                     σc = ηLηo Vf σf + (1-Vf ) σm                    4-2 
 
Therefore, equations 4-1 and 4-2 can be used to evaluate the effective mechanical 
properties of CNTs in the composites. In the calculation, the random 3D orientation 
value of 1/5 was chosen for ηo, ηL equals 1 for high fibre aspect ratios (1/d) > 100. 
The volume fractions were deduced from the weight fractions and densities of the 
materials. 
c 
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Fig. 4.7 (a) Effective Young’s modulus and (b) effective strength of MWNTs as 
calculated from the rule of mixtures, showing that scCO2 processed nanocomposites 
incorporating pristine MWNTs result in nanotube efficiency similar to that of 
melt-compounded and masterbatch based nanocomposites based on HDPE coated 
MWNTs. The line represents the upper-bound for nanotube moduli 
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Fig. 4.7 illustrates the back-calculated effective Young’s modulus and tensile stress 
of CNTs. Generally, the effective properties decrease with increasing nanotube 
content. The effective properties of pristine MWNTs in nanocomposites processed 
using scCO2 are as good as, or even better than, those for coated cMWNTs in 
nanocompsoites processed using melt-compouding and masterbatch. From direct 
individual CNT testing, Young’s moduli of the order of 1 TPa and tensile strength 
values ranging from 10 to 150 GPa have been reported in the literature 6-9. However, 
often back-calculated values of effective nanotube properties are significantly lower 
than experimentally measured values of isolated CNTs, presumably due to 
difficulties in achieving good dispersions of the nanotubes, a strong nanotube-matrix 
interface and nanotube alignment. Our calculated values of strength are reasonable 
among the experimental data for CNTs8,9. However, the effective modulus values, 
deduced from nanocomposites with a very low nanotube content (0.06 vol.%), are 
significantly higher than the theoretical modulus values for nanotubes indicated by 
the drawn line in Fig. 4.6a. The reason for this could be related to a modification of 
the matrix through the addition of CNTs, which can cause errors in the selected value 
of Em. Because of the high matrix content, the calculated results are strongly affected 
by the variation of Em. Small changes of Em values of 1.25 MPa to 1.40 MPa will 
result in an effective modulus reduction from 2435 GPa to 1200 GPa in the 
calculations. In Coleman et al. work, the Young’s modulus of the composites has 
been reported to increase with polymer matrix crystallinity10. Similar results were 
also shown in other studies that changes in the crystallinity and the crystalline 
morphology of the polymer matrix can have pronounced effects on the mechanical 
properties of nanocomposites11-13. 
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Table 4.2 DSC measurement results 
Sample CNT [wt.%] Tm [˚C] Tc [˚C] Xc [%]
Pure PP 0 166.0 110.3 37.9
 0.1  164.7 118.9 43.7
scCO2PP/MWNT 0.25  164.2 119.0 43.1
 1.0  165.0 119.9 41.0
 0.1  164.4 119.0 42.3
scCO2.mPP/MWNT 0.25  165.0 119.5 42.4
 1.0  164.4 119.9 43.4
 0.1  164.9 116.2 43.3
scCO2PP/cMWNT 0.25  164.4 115.7 44.6
 1.0  127.0 / 166.0 116.5 42.9
 0.1  164.2 115.5 43.7
scCO2.mPP/cMWNT 0.25  164.7 116.2 43.3
 1.0  127.3 / 165.7 116.4 43.7
melt.mPP/MWNT3 1.0 165.0 121.9 40.2
melt.mPP/cMWNT3 1.0 165.4 117.8 39.8
The melting temperature was calculated from the first heating, the crystallinity was 
calculated from the second heating, and the crystallization temperature was 
measured from the first cooling. 
 
DSC data of the melting temperature (Tm), the crystallization temperature (Tc) and 
the crystallinity (Xc) of the PP nanocomposites are presented in Table 4.2. The 
addition of nanotubes only slightly decreases the Tm of PP at 166 ˚C by 1 ˚C. A Tm of 
around 165 ˚C indicates the melting of α-crystals of PP. Additionally, samples with 
HDPE coated MWNT content above 0.5 wt.% show an additional broad peak at 
around 127 ˚C corresponding to the melting of the HDPE coating (Fig. 4.8). 
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Interestingly, the scCO2 processed sample before hot-pressing shows a broad peak in 
the 150-160 ˚C temperature range as well as the peak of 166 ˚C. This lower Tm 
around 155 ˚C, suggests the melting of polypropylene β-phase crystals12,14. Our XRD 
results also confirm the presence of a γ-phase of PP which is discussed in the text 
below. All samples after hot-pressing only show the Tm, at 166 ˚C, indicating no 
change to the PP α-crystals upon the addition of CNTs, which is in agreement with 
previous reports in the literature15,16. Therefore, it is assumed that the β and γ-phase 
crystal formation of PP during scCO2 processing was erased from the final specimens 
after hot-pressing.    
 
 
Fig. 4.8 The DSC heating scan for typical PP/MWNT nanocomposites, showing an 
additional broad peak at around 127 ˚C for samples with cMWNTs 
 
Tc and Xc are increased by the addition of MWNTs or cMWNTs into the PP, 
suggesting that nanotubes act as nucleating agents which reduce the spherulites’ size, 
induce the crystals’ growth at higher temperatures and enhance crystallization. 
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Furthermore, pristine MWNTs give a higher Tc of PP nanocomposites than cMWNTs, 
which indicates a stronger nucleation effect from MWNTs than from coated MWNTs. 
Clearly, the surface of any nucleating agent plays an important role in the 
crystallization process17,18. MWNTs have high surface energies which can absorb the 
polymer preferentially along their crystal structure and act as nuclei for polymer 
crystals. HDPE coatings decrease this surface free energy, resulting in a reduced 
nucleating efficiency. Results also show a small variation in the Tc with different 
CNT loadings. Although nucleating agents significantly increase the number of 
nucleation sites, above certain loadings the introduction of more CNTs may hinder 
chain mobility and retard crystal growth. This may explain the more pronounced 
nucleating effect observed for very low CNT loadings. Hence, the mechanical 
reinforcing effects observed are a combination of the modification of the PP matrix 
through increased crystallinity as well as true reinforcing effects from CNT fillers13. 
 
Fig. 4.9 shows the XRD patterns for pure PP and scCO2 processed nanocomposites 
before and after hot-pressing. MWNTs do not have peaks at 2θ < 25 °. The pattern of 
pure PP shows peaks corresponding to a PP α-phase at 2θ = 14, 17, 18.5, 21.5, 21.9 
and 25.4 ° for six major reflections: (110), (040), (130), (111), (041) and (060) plane, 
respectively19. For scCO2 processed pure PP and PP nanocomposites, an additional 
peak at 2θ of 20.1 ° is detected, which corresponds to the characteristic (117) plane 
of the γ-phase of PP20. The γ-phase is only obtained in some special cases such as 
under high pressure and by the crystallization of very low molar mass fractions20. In 
our case, the high pressure used in the scCO2 processing promoted the formation of 
γ-phase crystals. Apart from the peaks of α and γ-phases, a broad small peak 
observed at 2θ of 16° for the scCO2.mPP/cMWNT 0.5 wt.% sample before 
hot-pressing corresponds to the (300) plane of the β-phase of PP21. Other β-phase 
peaks such as 2θ of 16.7 ° (008) and 21 ° (301) are too close to the strong α-phase 
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peaks to be identified. The PP nanocomposite sample after hot-pressing only shows 
an α-phase of PP which is in close agreement with our DSC results, suggesting that 
the thermal history from scCO2 processing was erased after hot-pressing. The 
preferential orientation of PP crystals growth along the (040) planes is also found 
here with the addition of MWNTs in PP, similar to the phenomenon observed from 
PP/sepiolite nanocomposites (studied in Chapter 3).    
 
 
Fig. 4.9 X-ray diffraction spectra for typical PP/MWNT nanocomposites, confirming 
the presence of α-phase crystals of PP in the nanocomposites 
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Fig. 4.10 The TGA of PP/MWNT nanocomposites processed using scCO2 assisted 
mixing, showing a retarded thermal degradation of nanocomposites by the presence 
of MWNTs 
 
Finally, the thermal stability of the nanocomposites was investigated by TGA (Fig. 
4.10). The thermal degradation of PP is substantially retarded by the presence of 
CNTs. The onset decomposition temperatures, Tonset, are higher for PP/MWNT 
nanocomposites because the CNTs hinder the flux of degradation products and 
improve the heat dissipation within the composites22. However, above 470 °C the 
composites seem to degrade at a slightly higher rate than the neat polymer. A similar 
Tonset was observed for both the PP/cMWNT and PP/MWNT nanocomposites, 
indicating that the HDPE coating of cMWNTs had no significant effect on the 
thermal degradation behaviour. 
 
4.4 Conclusions 
 
This chapter described the preparation of PP/MWNT nanocomposites using the 
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scCO2 assisted mixing method and the results were compared with those processed 
by a traditional melt compounding method. Results showed that by using scCO2 
assisted mixing, both the yield stress and the Young’s modulus of the 
nanocomposites increase with MWNT loading. However, unlike in melt 
compounding processes, with which the use of HDPE coated MWNTs is essential for 
improved dispersion and properties, in the case of scCO2 assisted mixing, similar 
good dispersions and mechanical properties are achieved with pristine MWNTs, 
which in addition to obvious cost benefits may also benefit from a lower viscosity of 
the polymer melt under scCO2 conditions and a better preservation of nanotube 
lengths. It is interesting that techniques designed to achieve high quality PP 
nanocomposites, such as the use of masterbatches or polymer coated MWNTs, are 
not strictly necessary when using scCO2 assisted mixing. In accordance with many 
other nanocomposite studies, the addition of CNTs enhanced the PP nucleation 
process. The resulting increase in crystallinity is an important additional factor 
responsible for the enhanced mechanical properties of the final nanocomposites. 
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Chapter 5 
 
Drug Delivery Systems 
 
 
 
 
 
A wide variety of biomaterials are used as components of the various formulations 
and devices that are routinely used for delivering drugs to the body today.  These 
devices are referred to as being a drug delivery system (DDS), a system which 
releases drugs in a controlled manner1. So, why use a DDS? Let’s start with the 
changes in blood plasma levels following a single dose administration of a 
therapeutic agent. Fig. 5.1 shows that the blood plasma level rapidly rises and then 
exponentially decays as the drug is metabolised and/or eliminated from the body. 
The figure also shows drug concentrations above which the drug produces 
undesirable (e.g. toxic) side effects and below which it is not therapeutically 
effective. Although we can increase the size of the dose to achieve longer time for 
which the concentration of the drug is above the minimum effective level, blood 
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plasma concentrations will extend into the toxic response region (dotted line). 
Alternatively, safe doses can be repeatedly administered at periodic intervals to 
maintain a desired drug concentration level; however, this is inconvenient, and 
patient compliance is often poor.  
 
 
Fig. 5.1 Drug concentration as a function of time following absorption of a 
therapeutic agent1 
 
For these reasons, there has been great interest in developing sustained-release 
formulations and devices that can maintain a desired blood plasma level for a certain 
period of time without reaching a toxic level or dropping below the minimum 
effective level. The sustained-release systems became the primary objective of DDS 
to control the release of drugs. Nowadays, sustained-release systems are designed to 
achieve the controlled release of drugs by reproducible and predictable kinetics. Also, 
a concerted effort was made to develop controlled release systems for drug targeting, 
a method by which a drug is delivered to a specific tissue or organ using carriers or 
chemical conjugates2. Drug delivery is one of the most clinically-commercialised 
areas of biomaterials. The world market of advanced drug delivery systems was 
valued at $139 billion in 2009 and is estimated to be worth $196.4 billion by 20143. 
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Here are some commercial device examples. The Ocusert system, developed by Alza 
Corp., which is inserted in the lower cul-de-sac and releases pilocarpine in the 
treatment of glaucoma4. Capronor® is designed for contraceptive steroids based on 
the biodegradable polymer polycaprolactone to release levonorgestrel at a constant 
rate for one year and to completely bio-erode in three years5. Nutropin® is a product 
which encapsulates recombinant human growth hormone using 
poly(lactic-co-glycolic acid) (PLGA). It provides elevated blood plasma levels for 
more than one month6. Gliadel®Wafers is a unique form of treatment for brain 
tumours. It is based on polyanhydride wafers which slowly release carmustine (an 
anti-brain tumour drug) and can be implanted into the tumour site7. 
 
5.1 Types of Drug Delivery System 
 
There are several methods used to classify DDS. According to their delivery routes, 
DDS can be divided into four types: pulmonary delivery, oral delivery, transdermal 
delivery and other delivery routes8. The correct delivery route could significantly 
increase drug action efficiency and decrease its side-effects and systemic toxicity. All 
of these delivery routes could provide a novel drug delivery path for specific diseases 
at specific sites. 
 
According to the release mechanism, DDS can be classified into diffusion controlled 
DDS, water penetration controlled DDS, chemically controlled DDS, responsive 
DDS and particulate DDS9. Sometimes, one drug release device will release a drug 
under combinations of several of the release mechanisms mentioned above. For 
example, the drug release from biodegradable polymer devices can be controlled by 
the diffusion of the drug as well as the chemical degradation of the polymer carriers. 
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As mentioned in the previous context, DDS can also be classified into sustained 
release and drug targeting systems based on their action mechanism and functions. In 
this thesis, if not mentioned, controlled release means sustained release. 
 
According to materials utilized for drug delivery, there are two main groups: 
liposome-based drug delivery systems and polymer-based drug delivery systems. 
Small lipid vesicles known as liposomes have been extensively studied and 
encapsulating drugs within these vesicles has the potential advantage of providing a 
transdermal path and a higher drug delivery capacity10. The technology of polymer 
drug delivery has been studied in detail over the past 30 years and numerous 
excellent reviews are available8,11,12. A more detailed review of polymer drug 
delivery systems is stated in the following section.  
 
5.2 Design of Drug Delivery Devices 
 
In recent years, there have been numerous developments in designing different 
devices to fulfil various requirements in the field of drug delivery9. The most used 
designs are: 
 
z Drug surrounded by a thin polymer membrane (reservoir devices) 
z Drug uniformly dispersed or dissolved in a polymer matrix (monolithic devices) 
z Soluble polymers with covalently attached  pendant drug molecules 
z Osmotic pumps by which the drug release rate is controlled dynamically 
z Biodegradable reservoir and monolithic systems 
z Biodegradable polymer backbones with pendant drugs 
z Responsive smart systems, such as temperature- and pH-responsive, mechanical-  
and physically-responsive, self-regulated systems 
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z Polymeric colloidal particles or microencapsulates (microparticles, microspheres 
or nanoparticles) 
z Polymer drug conjugates 
z Polymeric micelles 
z Liposomes 
 
5.3 Polymer Drug Delivery Systems  
 
There is a range of polymers which have been employed to control the release of 
drugs. Polymer delivery systems can be classified into non-biodegradable and 
biodegradable delivery systems. However, in principle there is no sharp boundary 
between biodegradable and stable polymers. The difference between 
non-biodegradable and biodegradable polymers is a matter of degree, conditions and 
time scale. For example, proteins are biodegradable polymers which are degraded by 
the hydrolysis of the amide bond by the mediation of enzymes. Polyamides, which 
are widely used as non-biodegradable polymers, are also subject to enzymic 
degradation, but at a significantly lower rate. Therefore, classifying polymers into 
non-bio- and biodegradable is based on whether the polymer is used deliberately for 
its biodegradability or for its non-biodegradability1,8.  
 
5.3.1 Non-Degradable Polymer Delivery Systems 
 
The first polymer drug release system was based on non-biodegradable polymers. In 
1964, Folkman and Long reported the use of silicone tubes filled with drug 
suspension for sustained release13. Their findings initiated the field of controlled 
release technology and led to the development of Norplant®, a contraceptive which 
can remain therapeutically effective release for as long as five years13.  
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5.3.1.1 Overview of Non-Degradable Polymers  
 
To be successfully used in controlled drug delivery formulations, a material must be 
chemically inert and free of leachable impurities. It must also have an appropriate 
physical structure, with minimal undesired ageing, and be readily processable. Some 
of the materials that are currently being used or studied for controlled drug delivery 
include: polyurethanes14, silicones13, poly(2-hydroxy ethyl methacrylate)15,16, 
poly(vinyl alcohol)17, poly(vinyl pyrrolidone)18, poly(methyl methacrylate)19, 
poly(acrylic acid)20, polyacrylamide20, poly(ethylene-co-vinyl acetate)20, 
poly(ethylene glycol)21, poly(methacrylic acid)20,22, etc.  
 
5.3.1.2 Poly(ethyl methacrylate/tetrahydrofurfuryl methacrylate) 
 
In dentistry, to avoid repeated mouth washes, polymer drug delivery systems are 
being researched extensively for the release of antibacterial, anti-fungal and antiviral 
drugs in order to treat oral infections23. It is claimed that these systems have fewer 
side effects by comparison with conventional forms, because of the continual 
presence of the drug at the site of action, which means that a smaller amount of the 
drug is needed to achieve the therapeutic effect24. They were also believed to be of 
high benefit for both physically and mentally compromised patients25.  
 
Among the employed polymers, the poly(ethyl methacrylate/tetrahydrofurfuryl 
methacrylate) (PEM/THFM) polymer system is widely used and well 
documented26-30. This chemical structure is shown below in Fig. 5.2.  
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Fig. 5.2 The chemical structure of PEM/THFM 
 
The suitability of PEM/THFM in drug delivery applications is due to its various 
unique properties, which include: 
 
z Unusual water uptake properties. Although the solubility of THFM monomer in 
water is only 3 %, poly(THFM) absorbs more than 70 % water27. The 
mechanism is a two-stage process involving an initial Fickian process, followed 
by a stage characterised by a slower growth of droplets (clustering mechanism)27. 
The second stage is controlled by stress relaxation. If the clustering or stress 
relaxation can be prevented, the polymer behaves in an ideal, Fickian manner 
which will be perfect candidate for drug release. It has been shown that 
copolymerisation of THFM with other monomers, e.g., PEM, successfully 
suppresses this secondary process29,31. 
z Cold cure polymer systems. The polymerisation of the copolymer happens at 
room-temperature. This mode of polymerisation has a low polymerisation 
exotherm, which does not adversely affect the efficacy of the anti-fungal drugs28. 
It is proven that PEM/THFM has superior biocompatibility than poly(methyl 
methacrylate) and is more efficient at delivering drugs28. 
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PEM/THFM has been proved to be an effective system as a delivery vehicle for 
chlorhexidine diacetate23,25,26,28, fluoride release30, gentamicin28 and bone 
morphogenetic protein28,31. The system is also biocompatible with bone and used to 
promote bone and cartilage regeneration. 
 
5.3.2 Biodegradable Polymer Delivery Systems 
 
Non-biodegradable materials are stable and can be used easily to make specific 
structures. On the other hand, biodegradable polymers are polymers that are used in 
biomedical technology and medicine specifically for their biodegradability. 
Biodegradable delivery systems do not need to be surgically removed; they can be 
metabolized and excreted by natural pathways. Therefore, some of the problems 
related to the long-term safety of permanently implanted devices can be 
circumvented.  The polymer is used to protect a drug during its transfer through the 
body until it is released, or is used to control the release rate of a drug. Selecting a 
suitable polymer is critical to the design of a desired controlled release system. These 
degradable materials must fulfil more stringent requirements in terms of their 
biocompatibility than non-biodegradable materials. Since all the degradation 
products are released into the body of the patient, the potential toxicity requires 
careful consideration. 
 
5.3.2.1 An overview of Degradable Polymers 
 
Biodegradable polymers include natural, modified natural and synthetic polymers. 
Collagen, cellulose, and chitosan are examples of natural polymers. Natural polymers 
have been tested as drug delivery matrices for the delivery of protein based drugs. 
Modified natural polymers are natural polymers that are altered in order to suit a 
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particular application. The reason for the modification is that these polymers often 
take more time to degrade within the body. Over the past few decades, synthetic 
polymers have been actively studied for use in DDS. These include 
polyhydroxybutyrate, polyhydroxyvalerate, and copolymers thereof, 
polycaprolactone, polyanhydrides, polycyanoacrylates, poly(amino acids), 
polyphosphazenes, poly(phosphoesters), polyorthoesters, and polylactides (PLA), 
polyglycolides (PGA), and the copolymers PLGA16,32-34.  
 
Although a variety of polymers are available, degradable polymers are still too 
limited to cover a wide enough range of diverse material properties. Thus, the design 
and synthesis of new, degradable materials is currently an important research 
challenge.  
 
5.3.2.2 The Process of Biodegradation 
 
One of the most important prerequisites for the successful use of a degradable 
polymer for any medical application is a thorough understanding of the way the 
device will degrade and ultimately absorb from the implant site. The bio-erosion 
process of a solid, polymeric implant is associated with macroscopic changes in the 
appearance of the device, changes in its physical processes such as swelling, 
softening, deformation, stress cracking, or structural disintegration, weight loss, and 
the eventual depletion of the drug or a loss of its function8,11. 
 
The two main biodegradation mechanisms in biomedical polymers are hydrolysis 
and oxidation. These reactions may or may not be catalysed by enzymes, depending 
on detailed characteristics of the polymer itself (e.g., chemical structure, molecular 
weight (Mw), morphology), and on device shape and its location in the body.  
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Hydrolysis is the scission of covalent bonds by water. Susceptibility of polymers to 
hydrolysis depends on their chemical structure, morphology and dimensions, and 
also on their immediate environment. Hydrolysis may be catalysed by acids, bases, 
salts and enzymes.  
 
5.3.2.3 Two Modes of Biodegradation  
 
Two distinct modes of biodegradation have been described in the literature. They are 
surface erosion and bulk erosion35 (Fig. 5.3). 
 
 
Fig. 5.3 A schematic illustration of surface erosion and bulk degradation 
 
In “surface erosion”, degradation occurs when the penetration of water into the 
polymer bulk is much slower than the hydrolysis. The degradation process is limited 
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to the surface of the device. Therefore, the device will become thinner with time, 
while maintaining its structural integrity throughout much of the erosion process35. 
Alternatively, in “bulk erosion”, the rate of water penetration into the solid device is 
much faster than the degradation reaction; hence degradation takes place at nearly 
equal rates throughout the polymer surface and bulk. Because of the rapid 
penetration of water into the matrix of hydrophilic polymers, most of the currently 
available polymers will give rise to bulk eroding devices.  
 
Bulk erosion may be autocatalysed by the acidity of the degradation products, or 
changes in the biodegradation environment. This effect may lead, somewhat counter 
intuitively, to faster degradation in larger devices (lower surface to volume ratios), 
and inside the device bulk, due to the slower release of soluble acidic degradation 
product in larger devices.  
 
However, in practice, biodegradation must be regarded in terms of the various 
intermediates of these two extremes, i.e. in “erosion zones” of finite thickness at the 
surface where degradation takes place. Most typical examples of bulk and surface 
degrading polymers are aliphatic polyesters and polyanhydrides, respectively.  
 
5.3.2.4 Factors Influencing Biodegradation  
 
The rate of biodegradation of a given polymer is not an unchangeable property. The 
main factors that determine the overall rate of the biodegradation process are: 
 
z Polymer properties: crystallinity, Tg, Mw, Mw distribution, the 
hydrophilic/hydrophobic character of the repeat units, wettability (swelling, 
water uptake) 
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z The manufacturing process of the polymer devices: morphology, geometry 
(specifically the surface area to volume ratio) 
z External factors: temperature, pH, additives, enzymes 
 
5.3.2.5 Poly(lactic-co-glycolic acid) 
 
Among these biodegradable polymers, PLA and PGA and their copolymer PLGA 
have been investigated for more applications than any other degradable 
polymer16,32-34. The high interest in these materials is based, not on their superior 
materials properties, but mostly on the fact that these polymers have already been 
used successfully in a number of approved medical implants and are considered safe, 
non-toxic, and biocompatible by regulatory agencies. It has received abundant 
research for its effective usage in drug delivery. 
 
 
Fig. 5.4 The chemical structure of PLGA 
 
Fig. 5.4 shows the chemical structure of PLGA. PLGA has been successful as a 
biodegradable polymer because it undergoes hydrolysis to yield lactic acid and 
glycolic acid monomers and these two monomers are normal by-products of cellular 
metabolism in the body. Since the body deals effectively with the two monomers, 
there is very minimal systemic toxicity associated with using PLGA for drug delivery 
or biomaterial applications. 
 
The degradation of PLGA has been described very well as bulk erosion36. The 
erosion process can be split into 3 stages. In stage 1, water diffuses into the polymer 
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and ester bond cleavage starts producing a primary alcohol and a carboxylic acid. In 
stage 2, differentiation between the surface and interior begins, with a drastic 
decrease in molecular weight in the inner part of the matrix. The accumulation of 
carboxylic acid hydrolysis products will reduce the pH which will enhance 
hydrolysis inside the PLGA resulting in an autocatalysis of the hydrolysis reaction. 
However, the diffusion of the degradation segments out of the polymer is limited by 
their sizes, therefore, the mass of the PLGA will remain unchanged. In stage 3, a 
network of pores is formed allowing for the release of fragments, i.e. erosion occurs.  
 
PLGA degradation is strongly determined by the properties of the polymer. Different 
forms of PLGA can be obtained depending on the ratio of the lactide to the glycolide 
monomer used for the polymerisation. The higher the content of glycolide units, the 
lower the time required for degradation. A low molecular weight PLGA polymer 
degrades faster than PLGA composed of high molecular weight polymer chains. 
Since water does not penetrate as easily into the crystalline regions, the PLGA 
degradation rate is decreased with the increase of the crystallinity of the polymer33. 
Factors such as sample size, shape, and surface morphology can also influence 
PLGA degradation. 
 
5.4 Drug Release Prediction 
 
Mathematical modelling is used to aid in predicting the drug release rates and 
diffusion behaviour of these systems by the solution of an appropriate model. It also 
aids in understanding the physics of a particular drug transport phenomenon, thus 
facilitating the development of new pharmaceutical products. 
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5.4.1 Mechanisms of Drug Release  
 
 
Fig. 5.5 Drug release mechanisms for polymer drug delivery 
 
Depending on the release mechanism, the controlled release systems can be 
classified into diffusion-controlled, polymer degradation-controlled, 
swelling-controlled, and a combination of the above mechanisms, as shown in Fig. 
5.5. Diffusion is the principal release mechanism, and it takes place at varying 
degrees in both degradation and swelling-controlled systems37. The 
diffusion-controlled systems follow the fundamental Fick’s law. For 
degradation-controlled systems, the rate of drug release is controlled by oxidation, 
hydrolysis, enzyme assistance, or a combination thereof.   
 
The burst effect, an initial large portion of drug which is released before the release 
rate reaches a stable profile, has usually not been considered as one of the phases of 
release38. 
 
5.4.2 Kinetic Equations for Evaluation 
 
Drug release from polymer matrices has been described by kinetic models in which 
the dissolved amount of drug (Q) is a function of time (t). Modelling studies allow 
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the elucidation of underlying mass transport mechanisms and offer the possibility of 
predicting the effect of matrix design parameters (shape, size and composition of 
matrix tablets) on the resulting drug release rate39-51. The kinetic equations which 
have been widely applied are zero order, first order, the Higuchi equation and the 
Korsmeyer-Peppas equation, which is also called the power law. 
 
5.4.2.1 Zero Order Kinetics 
 
A zero-order equation describes a constant rate of drug release over time: 
 
Qt = Q0+K0t                               5-1 
 
Where Qt is the amount of the drug dissolved in time t, Q0 is the initial amount of the 
drug in the solution (most times, Q0 = 0) and K0 is the zero order release constant. 
The drug delivery system, following this profile, releases the same amount of drug in 
each unit of time and is the ideal method of drug release in order to achieve a 
pharmacological prolonged action40. The zero order model has a large application in 
coated dosage forms or membrane controlled dosage forms.  
 
5.4.2.2 First Order Kinetics 
 
A first-order equation can be rewritten as a log cumulative percentage of drug 
remaining vs. time: 
 
 L o g Qt = L o g Q0 – K1t/2.303                   5-2 
 
where Qt is the amount of the drug released in time t, Q0 is the initial amount of the 
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drug in the solution and K1 is the first order constant.41 In this way a graphic of the 
decimal logarithm of the released amount of drug versus time will be linear. The 
pharmaceutical dosage forms following this dissolution profile, such as those 
containing water-soluble drugs in porous matrices42, release the drug in a way that is 
proportional to the amount of drug remaining in its interior, and so that the amount of 
drug released in each unit of time diminishes.   
 
5.4.2.3 Higuchi’s Equation  
 
In 1961, Higuchi derived an equation to describe drug release from a planar system 
consisting of a homogeneous matrix in the form of an ointment base containing a 
finely dispersed drug43: 
 
 ,                 5-3 
 
Where q(t) is the amount of drug released after time t, A is the surface area of the 
ointment exposed to the absorbing surface, D is the diffusion coefficient of the drug 
in the matrix medium, and C0 and Cs are the initial drug concentration and the 
solubility of the drug in the matrix, respectively.  
 
The Higuchi equation describes a linear relationship between the cumulative amount 
of drug released and the square root of time, which is an indicator of diffusion 
controlled release (no erosion occurring)43. Although a planar matrix system was 
postulated in the original analysis, modified forms of equation 5-3 were subsequently 
applied to other types of matrices. Desai et al.44 employed inert matrix tablets with 
only one flat surface exposed to the dissolution media. Drug release was found to be 
linear with square root time. Lapidus and Lordi45 showed that when drug release was 
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restricted to a planar surface of a hydroxypropyl methylcellulose (HPMC) matrix 
tablet, linearity between drug release and square root time was observed even though 
the matrix was not inert. 
 
The classical Higuchi equations were derived under pseudo-steady state assumptions 
and, in general, cannot be applied to practical systems. The assumptions were 
summarized by Siepman and Peppas46: (i) the initial drug concentration in the system 
is much higher than the solubility of the drug in the matrix, (ii) mathematical analysis 
is based on one-dimensional diffusion (negligible edge effects), (iii) swelling or 
dissolution of the matrix is negligible, (iv) constant drug diffusivity and (v) perfect 
sink conditions are maintained. Although these assumptions are not valid for most 
hydrophilic matrices, the Higuchi equation is often employed to analyse the drug 
release to gain a rough idea of the underlying drug release mechanism due to its 
simplicity.  
  
Equation 5-3 is frequently written in simplified form47: 
 
        Mt/M∞ = Kt½                             5-4 
 
where Mt and M∞ are the absolute cumulative amounts of drug released at time  t 
and infinite time, respectively and K is the Higuchi dissolution constant. The drug 
release rate derived from the Higuchi equation predicts a zero intercept. However, 
negative or positive intercepts on the Y-axis might be obtained from a curve-fitting of 
dissolution data to the equation. The former indicates a failure of the drug delivery 
system to immediately attain a state of equilibrium diffusion described by the 
Higuchi equation (lag time) while the latter represents a burst release of the drug 
prior to the development of the diffusion-controlling barrier. 
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The analytical expression allows experimental determination of K from early release 
curves when Higuchi conditions are still prevailing.  
 
5.4.2.4 Korsmeyer-Peppas’ Equation (Power Law) 
 
The Higuchi equation does not apply to swellable polymer system because swelling 
leads to moving (diffusion) boundary conditions which violates one of the 
assumptions of the Higuchi equation. Korsmeyer et al.48 proposed the use of a simple, 
semi-empirical model, also known as power law, to describe drug release from a 
single face of a swelling hydrophilic matrix under perfect sink conditions:   
 
Mt/M∞ = Ktn                            5-5 
 
where Mt/M∞ is the fractional release of the drug, t is the release time, K is a kinetic 
constant characteristic of the drug/polymer system, and n is the release exponent 
indicative of the drug release mechanism. In 1987, Ritger and Peppas49, 50 showed 
that the equation can be used to describe the general drug release behaviour of 
non-swelling and swelling polymer matrices in the form of films, cylinders and 
spheres.   
 
Table 5.1 lists the values of n for different geometries of polymer matrices and the 
corresponding release mechanisms. For a polymer film or slab, when n = 0.5, pure 
Fickian diffusion operates and results in diffusion-controlled drug release. When n = 
1.0, case II transport is the predominant mechanism. It is in the same form as the 
zero-order equation Case II transport generally refers to the swelling-controlled 
systems due to the relaxation of the polymer chain. In addition to Case II transport 
(relaxation-controlled mechanisms), other mechanisms also give rise to linear drug 
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release kinetics. In swellable-erodible polymer matrices, a constant drug delivery rate 
can be achieved when a constant gel layer thickness is attained by synchronization of 
the swelling and eroding fronts40. A constant drug release rate was also observed with 
matrices consisting of low viscosity polymers where polymer dissolution controlled 
the rate of drug release51. An intermediate value of n (0.5 < n < 1.0) indicates a 
combination of Fickian diffusion and Case II transport, which is usually called 
anomalous transport or non-Fickian diffusion.  
For cylindrical and spherical matrices, the exponent n has a slight different value to 
identify the drug release mechanism. (Table 5.1) 
Table 5.1 The values of the exponent n in equation 5-5 and the corresponding release 
mechanisms from polymer delivery systems of various geometries 
 Exponent n  Release 
mechanism Film Cylinder Sphere 
0.5 0.45 0.43 Fickian diffusion 
0.5 < n < 1.0 0.45 < n < 0.89 0.43 < n < 0.85 Anomalous transport 
1.0 0.89 0.85 Case II transport 
The power law equation is only valid for the first 60 % of the drug release. However, 
recent work has shown that the equation can be applied to the entire release profile51. 
This model is generally used to analyse the release of a pharmaceutical polymer 
system, when the release mechanism is not well known or when more than one type 
of release phenomena could be involved.  
In order to choose the best model to study drug release phenomena, the coefficient of 
determination (R2), absolute sum of squares (sum of the squares of the vertical 
distances of the points from the curve), and the standard deviation of the residuals 
(standard deviation of the vertical distances of the points from the line) are 
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commonly used to compare the goodness-of-fit of the dissolution data to a model 
equation. 
 
5.4.3 Factors Influencing Drug Release 
 
Drug release from a polymeric matrix is affected by various factors including 
polymer properties, drug properties and the morphology of the matrix. Obviously, 
polymer properties are the fundamental factors when designing a drug delivery 
device in the first place. Drug properties include stability, solubility, charge, and 
protein binding propensity, etc. Morphology of the polymer matrix also plays an 
important role in governing the release characteristics of the encapsulated drug. The 
polymer matrix could be formulated as microspheres, gel, film, cylinders, rods etc. 
The shape of the polymer is important to the drug release kinetics, which has been 
described in detail in section 5.4.2.2. The surface morphology, porosity and the size 
distribution also affect the performance of the drug delivery device. 
 
5.5 Drugs Involved in the Study 
 
5.5.1 Chlorhexidine  
 
Chlorhexidine (CX) is a conventional antimicrobial drug which has been widely used 
to treat and prevent skin and mucosal infections with a low topical toxicity52. In 
addition, it has been demonstrated that chlorhexidine has a strong substantivity 
within the oral cavity, making it efficient in inhibiting dental plaque and gingivitis53. 
The structure of CX is symmetrical with two identical epitopes. (Fig. 5.6)  
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Fig. 5.6 The molecular structure of chlorhexidine 
 
CX is used as a rinse solution between 0.2 % and 0.5 % (w/v). However, the use of 
the mouth-rinse containing CX salt usually provides short-term efficiency, requiring 
repeated applications to maintain antibacterial activity. This shortcoming led to the 
use of controlled release devices for the long-term release54. Later development 
yielded devices made of an acrylic-based strip55, a cross-linked collagen chip56, and 
biodegradable polyesters57. Also, a number of researches were based on the 
PEM/THFM system26,28. 
 
5.5.2 Bovine Serum Albumin 
 
Despite the fast development of protein delivery systems, there are several problems 
facing protein delivery. The most significant issue is the denaturation and 
degradation. Proteins are polymers made up mainly of amino acids, which 
polymerize to give long chains that then fold into a functional 3-dimensional 
structure. This 3-dimensional structure, however, is held in place by weak forces that 
can be broken easily. Once this configuration is destroyed, the proteins lose their 
activity, and, in essence, are denatured. Proteins can lose their activity easily when 
subjected to adverse conditions such as high temperature, mechanical agitation and 
extreme pH etc. Protein stabilization is one of the most important issues that 
researchers must take into consideration during the design of controlled release 
systems. 
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Albumins form a group of acidic proteins which occur plentifully in body fluids and 
tissues of mammals and in some plant seeds. Albumins are readily soluble in water 
and their solution stability is very good. Albumin binds water, Ca2+, Na+, and K+. 
Due to a hydrophobic cleft, albumin binds fatty acids, bilirubin, hormones and 
drugs58. The main biological function of albumin is to regulate the colloidal osmotic 
pressure of blood.  The albumin form bovine serum (BSA) is widely used in the 
field due to its lack of effect in many biochemical reactions and its low cost since 
large quantities of it can be readily purified from bovine blood. BSA is a single 
polypeptide chain consisting of about 583 amino acid residues and no carbohydrates. 
The molecular weight of BSA has frequently been cited as 6643059. BSA is often 
used as standard in protein calibration studies. BSA is also the commonly used 
protein during the development of controlled release systems. To evaluate the 
characteristics of the polymer delivery vehicles, fluorescein isothiocyanate labelled 
BSA (FITC-BSA) has often been used as a model drug to allow the visualization of 
the protein localization within the microparticles and the detection of microparticles 
in cell cultures or tissues60. 
  
5.6 Techniques Involved in the Preparation of Drug Delivery System 
   
5.6.1 The Layer by Layer Technique 
 
Encapsulation is a process whereby particles are surrounded by a shell to give small 
capsules desired properties. This encapsulation can be achieved by a number of 
techniques such as phase separation, spray-drying, spray-coating, solvent evaporation 
etc. Amongst these methods, one technique, called layer-by-layer (LbL) 
polyelectrolyte assembling61, was established in 1992 and has been of great interest 
for the last 20 years. Initially, LbL polyelectrolyte adsorption utilised electrostatic 
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interaction between oppositely charged macromolecules at each adsorption to make 
multilayer films onto flat macroscopic substrates62. Then in the late 1990s, this 
technology was extended to non-planar surfaces by Sukhorukov et al. in the form of 
colloidal particles63. An “onion-like” structure was achieved by assembling 
multilayer of various polyelectrolyte combinations for colloidal particles. Once the 
desired number of layers has been assembled, the template particle is decomposed to 
form hollow polyelectrolyte microcapsules. The steps for microcapsule assembly are 
presented in Fig. 5.7. This enables an alternating polyelectrolyte assembly on 
different kinds of templates.  
 
 
Fig. 5.7 A schematic of general LbL assembly of polymeric microcapsules. a: coating 
a charged colloid with a polyelectrolyte and repeating with a second polyelectrolyte 
of opposite charge. b: the desired number of layers are obtained. c: decomposing the 
template. d: leaving a hollow polyelectrolyte capsule 
 
There are several general approaches using the LbL technique to encapsulate the 
biomacromolecules into polyelectrolyte capsules. Molecules like protein aggregates, 
dye or drug nanocrystals, and compact forms of DNA can be used as the template for 
LbL assembly, then leading to encapsulation64. The macromolecules can also be 
incorporated from the surrounding medium into preformed hollow capsules by 
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switching the permeability of the hollow capsule shell65. Another popular approach is 
that of using porous calcium carbonate (CaCO3) microparticles as the template to 
capture proteins inside polyelectrolyte microcapsules66. The porous CaCO3 
microparticles have a high adsorption capacity which benefits the encapsulation of 
proteins and other macromolecules. Protein-loaded CaCO3 microparticles can be 
prepared either by physical adsorption in which proteins are adsorbed from the 
solutions onto CaCO3 microparticles, or by coprecipitation in which proteins are 
captured in the growth process of CaCO3 microparticles. Then, the required number 
of polyelectrolyte layers poly(allylamine hydrochloride)/poly(sodium 
4-styrenesulfonate) (PAH/PSS) is assembled. Compared with physical adsorption, 
the coprecipitation procedure is very mild; coprecipitation was found to be about five 
times more effective than the former with the same amount of captured proteins; the 
concentration of protein inside the microcapsules can be controlled easily. Moreover, 
because it is universal, a wide range of macromolecular compounds and bioactive 
species can be encapsulated by the coprecipitation method. 
 
The LbL technique provides a unique architecture which is perfectly suited to the 
delivery of sensitive contents and active agents. Compared with other approaches, 
this method is quite simple and a high yield and tunable size of microcapsules can be 
achieved.  
 
5.6.2 Electrospinning  
 
Synthetic fibres, which can provide both physical and pharmaceutical support, have a 
wide range of applications in the biomedical field. Drug-loaded fibres have been 
proposed for a number of applications such as nanofibre-based supports for enzymes 
and catalysts, fibrous membranes for wound healing and scaffolds for tissue 
 
Chapter 5. Drug Delivery Systems 
 129
engineering67-70. The most commonly used technique for the creation of drug-loaded 
fibres is electrospinning. Electrospinning is a straightforward, relatively easy and 
cheap method. This technique involves drawing a continuous filament from a 
polymer solution or melt through a spinneret by high electrostatic forces and then 
depositing it on a grounded conductive collector (Fig. 5.8). The process offers the 
advantages of operating at ambient temperature and there being no coagulation 
chemistry involved. This ensures that the functionality of the drug is well preserved 
throughout the manufacturing process. The diameters of electrospun fibres can range 
from nanometers to micrometers. Extensive research based on PLA, 
poly(ethylene-co-vinyl acetate), PLGA, poly(ethylene glycol)-g-chitosan has taken 
place over the past few years and the drugs employed include tetracycline 
hydrochloride, ibuprofen, plasmid DNA, etc67,68,70,71. 
 
 
Fig. 5.8 A schematic illustration of electrospinning  
 
However, this method has still some unsolved problems: 
 
• Water-soluble drugs have proved difficult to incorporate in the process, because 
electrospinning requires a full dissolution of all the components in the polymer 
solution; 
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• The direct blend-electrospinning procedure leads to a high initial drug release 
from the fibres, and this burst release phenomenon reduces the effectiveness of 
the drug release system72;   
• The Denaturation and degradation of the bioactive agents happen during the 
preparation of the spinning solution and the electrospinning process due to the 
long exposure to harsh organic solvents73,74.  
 
To rise to this challenge, several improvements have been made. Water-in-oil (W/O) 
and oil-in-water (O/W) emulsions have been employed in the electrospinning 
processes to improve the incorporation of functional particles75. Coaxial 
electrospinning has also been designed and core-shell structures have been developed 
to protect bioactive agents. However, judicious adjustments of operational conditions 
were involved to ensure desired results76. Research into more effective modifications 
to electrospinning process is urgently required to address these issues. 
 
5.7 Objectives for Part 2 
 
Since sustained release is essential and an ultimate goal in drug delivery, the aim of 
the study for this part of the thesis was to develop polymer sustained release devices 
with improved efficiency of drug release. One non-biodegradable polymer and one 
biodegradable polymer were chosen.  
 
The PEM/THFM system is one of the most employed non-biodegradable polymer 
systems in DDS. It has been widely researched based on its use as a drug carrier for 
anti-fungal and anti-infection drugs to achieve prolonged antimicrobial activity 
locally. Changing the morphology of the polymer matrix, porosity for example, will 
have a great impact on the drug release profile as it is expected that porous structures 
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should enhance the release. Therefore, research was carried out based on a 
PEM/THFM system with the assistance of a scCO2 foaming technique. The research 
focuses are summarized as follows: 
 
1. To modify the traditional PEM/THFM copolymer system with the assistance of 
a scCO2 foaming technique 
2. To investigate the morphology, drug properties, and drug release efficiency 
under different fabrication conditions 
3. To investigate the drug release under different fabrication conditions 
 
As for biodegradable polymers, PLGA was chosen for its wide usage in the area of 
medical applications. PLGA has been employed as porous biodegradable matrices to 
guide tissue regeneration in the body. In addition, it can be modified by loading with 
growth factors, which can be released to enhance cell growth. The scaffold may also 
include additional residues for mimicry of extracellular matrix components or other 
biologically active molecules for therapeutic amelioration. Drug-loaded fibres have 
also been proposed for applications such as nanofibre-based supports for enzymes 
and catalysts and fibrous membranes for wound healing. However, the preparation 
procedure, electrospinning, is only valid for non-water soluble drugs and the harsh 
solvents involved significantly reduce the efficiency of the drugs. Therefore, the 
current study focuses on introducing a second barrier around the drug using the LbL 
technique in combination with electrospinning. It is believed that as such a new route 
for the impregnation of water-soluble drugs into PLGA fibres can be achieved. In 
detail, the research strategy was as follows: 
 
1. To fabricate PLGA fibres with water-soluble drugs using a combination of  
LbL techniques and electrospinning 
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2. To investigate the loading efficiency of the drugs, morphology, polymer 
properties and drug release efficiency under different fabrication conditions 
3. To study the mechanism of drug release from the fibres 
4. To explore the stability of the encapsulated drugs 
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Chapter 6 
 
Drug Release from Poly(ethyl 
methacrylate/tetrahydrofurfuryl methacrylate) 
Systems 
 
 
 
6.1 Introduction  
 
Changing the polymer morphology is one of the ways to influence drug release 
behaviour. A porous polymer matrix will enhance the drug release from the system. 
The applicability of supercritical fluid foaming technology has already proved to be 
beneficial in the area of biomedical and tissue engineering1-3. Barry et al.1 have 
demonstrated the potential usage of porous poly (ethyl methacrylate / 
tetrahydrofurfuryl methacrylate) (PEM/THFM) system as non-degradable scaffold 
for the tissue engineering of cartilage. They applied scCO2 foaming technique to 
fabricate the porous structure of the polymer and studied the effects of changes in the 
processing conditions on the porosity, pore size, etc. Described in this Chapter, 
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research focused on the applications of PEM/THFM system in the drug delivery. 
Traditionally cured PEM/THFM system was foamed by scCO2 and used as a drug 
carrier. Chlorhexidine (CX) was chosen as the dispersed drug. The morphology, 
density and porosity of the system were studied. The effects of scCO2 foaming 
conditions on the CX release behaviour were investigated. Higuchi’s model and 
Korsmeyer-Peppas’ model were used to study the drug release kinetics. 
 
6.2 Experimental  
 
6.2.1 Materials and Equipments  
 
PEM, a powder containing 0.6 wt.% residual benzoyl peroxide was used as supplied 
(Bonar polymers Ltd, Newton Aycliffe Co., Durham, UK). The THFM was obtained 
from Rohm Chemie, GmbH (Darmstadt, Germany) and the 
N,N-dimethyl-p-toluidine was acquired from Aldrich (UK). The chlorhexidine 
diacetate salt hydrate was purchased from Sigma (UK) (Fig. 6.1). All materials were 
used as supplied without further purification.  
 
 
Fig. 6.1 The molecular structure of chlorhexidine diacetate salt hydrate 
 
A liquid withdrawal CO2 cylinder at 725 psi pressure was supplied by BOC gases. 
The CO2 was chilled to -6 °C before being delivered via an Isco model 100D syringe 
pump with a chilled piston barrel. The custom made 450 ml high pressure autoclave 
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as described in Chapter 3 was used in all experiments. In addition, without exception, 
the water used was prepared in a three-stage Millipore Milli-Q Plus 185 purification 
system and had a resistivity higher than 18.2 MΩcm. 
 
6.2.2 Synthesis 
 
All samples were initially prepared using a similar procedure as follows: The CX 
was blended with the PEM powder at 3 levels, 6 wt.%, 12 wt.% and 18 wt.%. The 
N,N-dimethyl-p-toluidine (DMPT: a room temperature polymerization activator) was 
added to the THFM monomer at a level of 2.5 vol.% The CX-PEM powder was 
added to the THFM monomer at a ratio of 1 g powder to 0.6 ml monomer. After 
mixing, the material was placed in the circled cavity of a Teflon mould, 13.5 mm × 
1.5 mm, between two microscope slides covered with acetate sheets. Then, the 
sandwiched mould was held together under a pressure of ca. 29 psi and allowed to 
cure at room temperature for 12 hr.  
 
ScCO2 assisted foamed samples were prepared as follows: samples were placed into 
the autoclave which was sealed and filled with liquid CO2 at 725 psi. The 
temperature of the autoclave was then held at 40 °C and different pressures were 
applied for various periods. All conditions are listed in Table 6.1. At the end of the 
experiment, the CO2 was released over a period of 5 min or 30 min.  
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Table 6.1 Supercritical CO2 conditions applied 
 
6.2.3 Characterization  
 
All the specimens were freeze dried over 22 hr before any characterization.  
  
X-ray powder diffraction (XRD) data were recorded using a Siemens D5000 
Diffractometer, for which the X-ray beam was Cu-K radiation (kα1 = 1.5406 Å) and 
Name CX loading 
[wt.%] 
T [°C] P [psi] Tsaturation Tdepressurization 
6%2200psi3hr5min 6 40 2200 3hr 5 
6%2200psi3hr30min 6 40 2200 3hr 30 
6%1300psi3hr5min 6 40 1300 3hr 5 
6%1300psi3hr30min 6 40 1300 3hr 30 
12%2200psi3hr5min 12 40 2200 3hr 5 
12%2200psi3hr30min 12 40 2200 3hr 30 
12%1300psi3hr5min 12 40 1300 3hr 5 
12%1300psi3hr30min 12 40 1300 3hr 30 
18%2200psi3hr5min 18 40 2200 3hr 5 
18%2200psi3hr30min 18 40 2200 3hr 30 
18%2200psi1hr5min 18 40 2200 1hr 5 
18%2200psi1hr30min 18 40 2200 1hr 30 
18%1300psi3hr5min 18 40 1300 3hr 5 
18%1300psi3hr30min 18 40 1300 3hr 30 
18%1300psi1hr5min 18 40 1300 1hr 5 
18%1300psi1hr30min 18 40 1300 1hr 30 
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the radiation operated at 40 kV. Data were collected over the 2θ range 5-45 º with a 
step size of 0.01 º and a step time of 1 sec. 
 
SEM was carried out on the products using a JEOL 6300 (accelerating voltage 10 
kV). Prior to examination, samples were mounted onto 5 cm diameter circular 
aluminium stubs using carbon cement, coated with gold.  
 
The DSC was calibrated using a pure sample of indium. For DSC runs, samples were 
carefully weighed in aluminium pans and covered with aluminium lids incorporating 
a pinhole. DSC curves were obtained from the first heating run at a rate of 10 °C/min 
under a dry nitrogen atmosphere from 30 to 200 °C. 
 
Fourier transform infrared spectroscopy (FTIR) spectra were obtained using a 
Thermo Nicolet FTIR 8700 spectrometer equipped with a drift cell. Spectra were 
obtained at 8 cm-1 resolution, averaging 256 scans. The sampling chamber of the 
photoacoustic cell was pre-purged with helium. 
 
The skeletal density was determined by automated helium displacement pycnometry 
using the Ultrapycnometer 1000 (Quantachrome) using a known mass of foamed 
samples under vacuum at room temperature.  
 
Mercury intrusion porosimetry was performed using the PoreMaster 60 porosimeter. 
Pressure intrusion porosimetry (0-60000 psi) was employed to obtain pore diameter 
distributions in the range of 3.6 nm-360 µm.  
 
The release of CX from supercritical fluid foamed CX-PEM/THFM samples was 
monitored using UV-Vis spectroscopy dissolution tests (LAMBDA 950 
 
Chapter 6. Drug Release from PEM/THFM systems  
 145
Spectrophotometer). 100 ml of sterile deionized water was used as the dissolution 
medium and was maintained at temperature of 37±0.5 °C, stirred with a magnetic 
stirrer at a rate of 100 rpm. Samples containing an equivalent quantity of 20 mg CX 
were immersed in the medium. 3 ml aliquots were collected and the same volume of 
fresh deionised water was immediately replaced. The aliquots were obtained at 2 hr, 
6 hr, and 1, 2, 3, 4, 7, 9, 11, and 14 days, respectively. The CX concentration was 
determined using a UV-Vis spectrophotometer and the UV absorption was measured 
at 255 nm. The concentration of CX in the solution was calculated using the 
calibration curve established using a known concentration. The cumulative 
percentage of CX release over time was calculated using a spreadsheet package 
(Microsoft Excel).  
 
6.2.4 Mathematical Modelling of Drug Release Kinetics 
 
Data obtained from in-vitro release studies were analyzed according to different 
kinetic equations to identify the drug release mechanisms. The kinetic models 
studied were Higuchi’s model and Korsmeyer-Peppas’ equation, which are described 
in detail in Section 5.4.2. 
 
6.3 Results and Discussion 
 
6.3.1 Morphology 
 
Using scCO2 during processing has led to materials with significantly porous 
morphologies and micro-cellular polymer formation. The morphologies of all the 
scCO2 treated samples are presented in Fig. 6.2. The unfoamed traditional sample is 
glassy opaque. After foaming with scCO2, the samples lost the glassy opaque 
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appearance and became white. Also, the sizes of the samples after scCO2 treatment 
were bigger compared with traditional dense samples. CO2 depressurization time of 
30 min clearly resulted in a bigger size than 5 min for all the samples treated with 
1300 psi saturation pressure. 5 min depressurization time allows a more rapid loss of 
gas through the fast diffusion of CO2 which results in a low expansion ratio. By 
contrast, the reduced rate of gas lost in 30 min gives a higher expansion ratio. 
However, for samples treated under 2200 psi CO2 condition, there was no obvious 
size difference with different depressurization times, regardless of the CX content. 
The possible reason for this is that CO2 at 2200 psi possess much more gas than CO2 
at 1300 psi, so the depressurization rate of both 30 min and 5 min are relatively fast 
and so did not produce a significant difference in the expansion ratio. 
 
 
Fig. 6.2 The morphologies of traditional cured and scCO2 foamed 6 wt.% CX 
samples under different scCO2 processing conditions  
 
SEM images were obtained for scCO2 foamed samples with different CX content. 
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Fig. 6.3 shows a porous core structure encased by a nonporous skin after scCO2 
foaming processing. Previously, it was found that the thickness of this non-porous 
skin decreases with increasing CO2 saturation pressure with PMMA4. This was 
suggested by our results with PEM/THFM as well (Fig. 6.3b).  
 
 
Fig. 6.3 SEM images of scCO2 foamed 6 wt.% CX samples showing dense skin with 
porous foam structure inside treated under (a) 1300 psi and (b) 2200 psi 
 
The porous structure of the polymer was produced based on the expansion of a 
gaseous phase dispersed throughout the polymer melt. In other words, they are 
produced through the utilization of the thermodynamic instability of a gas and 
polymer system5. Three major steps must be performed in order to make use of such 
instability: saturation of a polymer with CO2; formation of expandable bubbles 
(nucleation); cell growth and density reduction. The critical parameters for 
controlling foam development in a CO2 foaming process are the concentration of 
CO2 in the polymer and the rate of CO2 escaping from the polymer6. 
 
 
(a) (b) 
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Fig. 6.4 Images showing scCO2 treated samples with different depressurization time 
Other processing conditions: 1300 psi saturation pressure, 3 hr saturation time. Pure 
PEM/THFM sample (a) 5 min, (b) 30min. 6 wt.% CX-PEM/THFM samples: (c) 5min, 
(d ) 30 min 
 
The study on the effect of depressurization time was carried out while keeping other 
operating conditions constant, e.g., 1300 psi saturation pressure with 3hr saturation 
time. When depressurization occurred rapidly at 5 min, the samples displayed a small 
pore structure (Fig. 6.4a and c) compared with the larger pores obtained by the slow 
30 min venting process (Fig. 6.4b and d). A difference in depressurization time gives 
a different depressurization rate, which plays an important role in the foaming 
process. A faster depressurization rate resulted in higher supersaturation, leading, in 
turn, to a higher nucleation rate. Decreasing the depressurization rate permits the 
(a) (b) 
(c) (d) 
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nucleation sites to grow into larger pores, whilst also allowing the pores to coalesce 
into more open structures7. This effect has been proved by many reserachers2,7-9. In 
Barry et al.’ research on PEM/THFM, within 30s vent, pore size is found within 50 - 
150 µm and 200 - 900 µm for a 60 min vent2. Similar observations have also been 
found for other foamed polymer systems previously, such as PS, PLGA and PMMA 
7-9.  
 
 
Fig. 6.5 SEM images showing 6 wt.% CX-PEM/THFM samples treated with scCO2 
under different saturation pressure: (a) 1300 psi and (b) 2200 psi. Processing 
conditions: 3 hr saturation, 30 min depressurization 
 
The effect of saturation pressure, in which 1300 and 2200 psi were chosen; on the 
foam structure was studied keeping the other parameters constant, e.g., 3 hr 
saturation time and 30 min depressurization time. The images in Fig. 6.5 show that 
the pore size is shifted towards smaller sizes and size distribution becomes narrower 
with increased CO2 saturation pressure. The saturation pressure directly determines 
the concentration of CO2 in the polymer. With increasing saturation pressure, the 
concentration of CO2 in the matrix increased, as well as the dissolution of CO28,10. 
Therefore, a greater amount of CO2 is incorporated into PEM/THFM at a higher CO2 
saturation pressure, providing more CO2 molecules for foaming upon the release of 
(a) (b) 
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pressure. This will produce a higher nucleation density due to lower interfacial 
tension and viscosity in the polymer matrix. A change in temperature has an effect as 
well8. An expansion in the gas will cause a drop in temperature. Lower saturation 
pressure produces a smaller temperature drop, hence the actual temperature 
following depressurization is higher, by comparison. Therefore, in this case, pores 
have more time to grow before they are frozen. Moreover, although the 
depressurization time is the same, the depressurization rate for 1300 psi is much 
slower than for 2200 psi due to the pressure difference, which also favours larger 
pores, as discussed in the previous paragraph.  
 
A comparison of the porous structure of the samples with different CX content is 
presented in Fig. 6.6. The images of 18 wt.% CX samples show more CX particles, 
which is as expected. With the increase of the CX content, the size of the pores 
becomes smaller and CX particles inside the matrix decrease the available free 
volume in the matrix. During polymer expansion, the CX particles tend to lock the 
polymer chains and decrease the CO2 absorption in the polymer. During the 
depressurization, CX particles inhibit the escape of CO2 from the polymer and give 
less opportunity for CO2 expansion; thereby promoting slow pore growth leading to 
smaller pore structures.  
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Fig. 6.6 SEM images of scCO2 foamed samples containing (a) pure PEM/THFM (b) 
6 wt.%, (c) 12 wt.% and (d) 18 wt.% CX under 1300 psi for 3 hr with 30 min 
depressurization time 
(a) 
(b) 
(c) 
(d) 
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The effect of changing the saturation time was studied by saturating of the sample 
under scCO2 conditions for 1 hr or 3 hr with other parameters remaining constant. 
The difference is not obvious between the results for 6 wt.% CX samples and those 
from the SEM observation. However, with the increase of the CX constant, for 
samples with 18 wt.% CX, a shorter saturation time (1 hr) produced a broader 
distribution of large pores (Fig. 6.7), while a longer saturation time (3 hr) produced 
smaller pores with a narrow distribution. CO2 might not be distributed uniformly 
throughout the polymer within a short saturation time especially with more CX 
particles inside the matrix retarding the absorption of the CO2. While longer 
saturation time allows for a full diffusion of CO2 into the polymer, leading to more 
uniform porous structures.  
 
 
Fig. 6.7 SEM images of 18 wt.% CX samples treated with scCO2 under different 
saturation times: (a) 1 hr and (b) 3 hr. Processing conditions: 1300 psi saturation 
pressure, 30 min depressurization 
. 
Helium pycnometry was used to analyse the density of the samples. For scCO2 
treated samples, the non-porous skin was removed prior to the measurement. The 
densities of traditional and scCO2 foamed samples, the comparison of the densities in 
terms of CO2 depressurization time and the CO2 saturation pressure are presented in 
Fig. 6.8. ScCO2 foaming significantly decreases the density of the sample as 
(a) (b) 
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expected. Increasing depressurization time from 5 min to 30 min results in a lower 
density for all samples (Fig. 6.8b), which agrees with the microscope results showing 
higher expansion ratios for samples with longer depressurization time. Moreover, 
higher CO2 saturation pressure (2200 psi) results in a slightly lower density than for 
those using 1300 psi (Fig. 6.8c).  
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Fig. 6.8 A comparison of the densities of the samples in terms of (a) traditional vs. 
foamed samples under 1300 psi saturation pressure, 3hr saturation time, 5 min 
depressurization time (b) CO2 depressurization time and (c) CO2 saturation pressure. 
Both (b) and (c) are under 3hr saturation time. 
 
Table 6.2 The porosity of traditional cured and scCO2 foamed samples (operation 
condition: 1300 psi saturation pressure, 3 hr saturation time, 30 min 
depressurization time) 
 
The pore structure was also analysed by MIP. The data of the mean pore diameter 
and porosities are summarized in Table 6.2. It was found that the porosity and mean 
Sample  Mean pore diameter [µm]  Porosity [%]
Traditional pure PEM/THFM 0.19±0.03 0.73±0.1
Foamed pure PEM/THFM 25.9±2.2 80.1±1.2
6 wt.%  22.1±3.6 70.1±2.3
12 wt.%  19.3±1.9 56.2±1.3
18 wt.%  18.0±3.3 49.4±5.3
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pore size significantly decreased when the content of CX increased. (from 70 % 
porosity for 6 wt.% CX samples to 49 % porosity for 18 wt.% CX samples). 
Although the porosity results are in agreement with the SEM observations, these 
images show much larger pore diameters (in the order of 200 µm). Barry et al.2 also 
witnessed this phenomenon and they attributed this finding to the differences in the 
theories of these two techniques. Porosimetry measures the diameter of the pore 
opening can be smaller than the pore cavity diameter2. Therefore, when a large 
number of very small pore openings (< 20 µm) is presented, the result detected by 
porosimetry would be dramatically smaller than the one observed from SEM. The 
combination of different methods in the analysis facilitates the extraction of 
information in a more exhaustive way. 
 
6.3.2 Thermal Analysis 
 
The thermal behaviour of materials is examined by DSC analysis, which is presented 
in Fig. 6.9. A peak at around 152 ºC which indicates the melting of crystallized CX 
can be observed in all the CX-PEM/THFM samples. A glass transition temperature 
(Tg) of around 55 ºC for PEM/THFM polymer systems was also observed. The 
scCO2 foamed samples show higher Tg than unfoamed samples regardless of CX 
content. Fig. 6.6 only presents the foamed sample of 18 wt.% CX content. (Tg around 
55 ºC) Data of samples of other CX content can be found in Table 6.3.  
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Fig. 6.9 The DSC curves for traditional cured pure PEM/THFM, 6 wt.%, 12 wt.%, 
18 wt.% CX content samples and scCO2 foamed 18 wt.% CX samples. (operation 
condition: 1300 psi  saturation pressure, 3 hr saturation time, 30 min 
depressurization time) 
 
Table 6.3 DSC data of Tg onset and Tm of samples 
Sample  Tg [ºC] Tm [ºC]
Pure PEM/THFM 54 --
Pure CX -- 156.3
6 wt.% 51 150.4
6%1300psi3hr5min 61 152.4
6%2200psi3hr5min 63 151.5
12 wt.% 50 152.8
12%1300psi3hr30min 61 154.5
12%2200psi3hr30min 64 153.8
18 wt.% 51 153.9
18%1300psi3hr5min 63 155.3
18%2200psi3hr5min 63 156.0
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6.3.3 FTIR Results   
 
FTIR spectra of the scCO2 foamed CX-PEM/THFM samples were collected and 
compared with the traditional cured samples (Fig. 6.10). The peak at 1635 cm-1 
indicates a C=N stretching from the CX. The carbonyl bands (C=O) of PEM and 
THFM in the traditionally cured system were observed at 1731 and 1719 cm-1, 
respectively (Fig. 6.10a). Only one single peak of C=O was observed in the 
traditionally cured CX-PEM/THFM samples. This peak slightly shifted to lower 
wave numbers (1727 cm-1) with the increase of CX content (18 wt.%). Similarly, 
scCO2 foamed CX-PEM/THFM systems have the same trend with drug loading (Fig. 
6.10b). Gong et al.11 found a larger shift of C=O peak (from 1724 to 1704 cm-1) in 
the scCO2 samples with the increase of CX content suggesting H-bonding interaction 
with the N-H groups of CX molecules. However, in this study, the shift is too tiny 
and happens in both traditional and foamed samples. The evidence is not good 
enough to conclude that the same interaction between polymer matrix and drug 
molecules appears after being treated with scCO2 in this case. For the scCO2 treated 
samples under different scCO2 conditions, no obvious differences are observed in the 
FTIR curves.  
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Fig. 6.10 The FTIR curves of (a) traditionally cured and (b) scCO2 foamed 
CX-PEM/THFM systems with different CX content 
(a) 
(b) 
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6.3.4 XRD Results 
 
 
Fig. 6.11 XRD analysis for pure CX, traditional cured samples (12 wt.% CX) and 
scCO2 foamed samples (12 wt.% CX) 
 
The crystallinity of CX was analysed by XRD. The XRD patterns of pure CX 
powder and cured CX-PEM/THFM systems, both before and after scCO2 processing, 
are presented in Fig. 6.11. The XRD pattern of pure CX powder shows strong 
characteristic peaks. After being cured in the PEM/THFM system, the peaks showing 
characteristic CX is still notable, which suggests the existence of the crystallized CX 
within the traditionally cured mixture. After being treated with scCO2, no sharp 
characteristic peaks of CX are observed, which may suggest a decrease in 
crystallinity of CX in the polymer system. However, this decrease in crystallinity is 
so small that it can not be detected by DSC analysis, as discussed in the previous 
section.   
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6.3.5 Drug Release Studies 
 
Drug release studies were carried out on scCO2 foamed samples using UV-Vis 
spectrophotometry. A calibration curve was made to calculate the unknown 
concentration of CX in the solution. In UV-Vis spectrophotometry, an absorbance 
value is linearly correlated to solution concentration obeying the Beer-Lambert law12, 
 
bcA ε=                             6-1            
 
where A is the absorbance, ε is the molar absorbtivity (Lmol-1cm-1), b is the path 
length of the sample (cm), and c is the concentration of the compound in solution 
(molL-1). A calibration curve is a plot of absorbance versus solution concentration, 
which is used to determine the concentration in an unknown solution by measuring 
its absorbance. The calibration curve of CX with UV-Vis at 255 nm shows a good 
linearity, R2 = 0.999 over the range 2.5-35.7 mg/L. (Fig. 6.12). 
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Fig. 6.12 The calibration curve for CX at 255 nm 
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Fig. 6.13 The release of CX from scCO2 foamed samples containing 12 wt.% CX 
(40 °C and 1300 psi for 3 hr and 30 min as releasing time) 
 
Both the traditionally cured and scCO2 foamed samples (with or without non-porous 
skin) are studied for drug release behaviour. The skin was cut off before testing for 
samples without skin. Fig. 6.13 shows the typical drug release curve of the 
percentage of CX released from the samples plotted against time. The release of CX 
from the traditional cured PEM/THFM system achieved a high initial release 
followed by a slower diffusion-controlled process and in total 7 % of CX was 
released in 14 days and 50 % of the total amount of CX released appeared in the first 
24 hr. The scCO2 foamed sample with the non-porous skin shows a similar level of 
drug release to that of traditionally cured samples, while drug release from samples 
without skin occurred much faster; approximately 4 times as much CX was released 
from the specimen (up to 25 %) over 14 days. The dense PEM/THFM matrix absorbs 
up to 30 % water in two stages: a rapid Fickian process followed by the development 
of discrete clusters of water at, as yet, unidentified osmotically active sites13,14. In the 
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presence of CX, the initial burst reflects surface release. Water diffuses into the 
matrix and the water cluster forms around CX particles to dissolve the drug upon 
contact. The drug particles, once dissolved, leave behind pores in the polymer matrix. 
The drug molecules can then diffuse out through the interconnecting pores. The slow 
diffusion-controlled release is controlled by the water uptake process of the polymer 
and the diffusion of the CX molecules. When the sample was foamed by scCO2, the 
porous structure significantly promoted the water uptake and the diffusion of the CX 
molecules and therefore, a faster release of CX was achieved. This relative faster 
release of CX is expected to be related to porosity and the pore size of the sample, 
which will be discussed in more detail in terms of CX content, CO2 saturation time 
and depressurization time. For the foamed sample with skin, the non-porous skin acts 
as a barrier inhibiting this advantage and controls the whole process when present on 
the surface of the specimen.  
 
  
Fig. 6.14 The release of CX from scCO2 foamed samples containing 6 wt.% and 18 
wt.% CX. All the samples were treated under scCO2 at 40 °C and 2200 psi for 3 hr 
and 30 min as releasing time 
 
Chapter 6. Drug Release from PEM/THFM systems  
 163
The samples having different CX loadings are compared in Fig. 6.14. An increase in 
the loading of the drug affecting the release kinetics has been reported earlier. In a 
study of CX release from traditional PEM/THFM systems, the release percentage of 
CX was higher with an increased loading of the drug15. In this study, although the 
actual amount of CX released from the 18 wt.% sample is higher than that from the 6 
wt.% one, the release in percentage of load terms is lower. The release rates were 
increased with an increase in the effective pore size. With the increase in drug 
loading, the pore size became smaller (Fig. 6.6), which retarded the water penetration 
into the polymer matrix, thus reduced the release rate of the drug.  
 
 
Fig. 6.15 The release of CX from scCO2 foamed samples containing 12 wt.% CX 
treated under scCO2 at 40 °C 3 hr and 5 min as releasing time 
 
Fig. 6.15 compares the CX release for samples processed under different scCO2 
holding pressures. The 2200 psi sample gives a higher release rate than the 1300 psi 
sample. The 2200 psi sample has a lower density indicating a higher porosity of the 
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sample, which could speed up water uptake by the polymer and diffusion of the CX 
molecules, thereby causing a higher CX release rate.   
                         
Fig. 6.16 The release of CX from scCO2 foamed samples containing 12 wt.% CX 
treated under scCO2 at 40 °C and 1300 psi for 3 hr with a releasing time of 5 min 
and 30 min 
 
Fig. 6.16 shows that the release rate of the sample, with 30 min as releasing time, is 
higher than that of the sample processed using 5 min as the releasing time. The 
bigger pores in the 30 min release time sample may enhance the water uptake in the 
polymer and dissolve the CX inside the polymer, while for the 5 min release time 
sample, the smaller and more even pores may cause higher surface tension and 
prevent water permeation (Fig. 6.4).  
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Fig. 6.17 The cumulative release of CX versus square root time profile (Higuchi’s 
model) for scCO2 foamed samples containing 12 wt.% CX (40 °C and 1300 psi for 3 
hr and 30 min as releasing time)  
 
 
(a)                       (b)                       (c) 
Fig. 6.18 Effect of processing conditions on the Higuchi release rate (drug 
released %/time1/2) of (a) CX content (b) CO2 saturation pressure and (c) CO2 
depressurizaiton time 
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Both Higuchi’s model and the Korsmeyer-Peppas model were chosen to interpret the 
drug release mechanism. The parameter used to compare the goodness-of-fit is the 
coefficient of determination R2. The linear profile of Fig. 6.17 suggests that CX 
release from the scCO2 foamed sample is consistent with a Fickian diffusion 
mechanism. The positive intercept on the Y-axis represents a burst release of the drug 
prior to the development of the diffusion-controlling mechanism16. The rate of drug 
release was calculated from the slope of the Higuchi curve expressed as % CX 
released/min0.5 (Fig. 6.18). An increase in CX loading and a decrease in CO2 
saturation pressure or CO2 depressurization time results in a decrease in drug release 
rate due to a decrease in total porosity of the matrices (initial porosity plus porosity 
due to the dissolution of the drug). The influence of the pore creation and 
enlargement by the increased CX particles is so small by comparison.  
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Fig. 6.19 Linear relations between the log(% CX released) vs. log(time) with the line 
slope being equal to the exponent n in the Korsmeyer-Peppas model for scCO2 
foamed samples containing 12 wt.% CX (40 °C and 1300 psi for 3 hr and 30 min as 
releasing time)  
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The data were also fitted using the Korsemeyer-Peppas model to further evaluate the 
release mechanism. Accordingly, in Fig. 6.19, log(% of released CX) is plotted as a 
function of log(time). The resulting linear plots permit the determination of the 
release exponents n, which will give information about the release mechanism. From 
Fig. 6.19, the release exponents were 0.285 which is beyond the limits of the 
Korsmeyer-Peppas model. The power law can only give limited insight into the exact 
release mechanism of the drug. It has been reported that drug release from a porous 
system may lead to n < 0.45. Gong et al. has found that for the foamed 
CX-PEM/THFM system, the drug release rate was found to be in agreement with the 
1/3 (n = 1/3) power law11. This unusual release behaviour is related to the porosity 
and nature of the matrix, and the rate of water uptake. 
 
6.4 Conclusions  
 
A foamed CX-PEM/THFM drug delivery system was successfully prepared by 
scCO2 processing. Different experimental conditions have been investigated. ScCO2 
efficiently foamed the drug polymer system and produced a highly porous structure, 
which dramatically increased the release rate of CX by comparison with traditional 
unfoamed systems. By altering the processing conditions, such as CO2 saturation 
time and depressurization time, we can modulate the porosity and pore size of the 
foamed samples, and drug release rate can be tailored accordingly. There is no 
evidence of changes in the CX structure or of interaction between the polymer and 
CX during scCO2 processing. The drug release kinetics of this formulation 
corresponds well with Higuchi’s model which indicates that CX is consistent with a 
Fickian diffusion mechanism. The n value calculated from the Korsmeyer-Peppas 
equation is beyond the limits of this model and appears to be related to the porosity 
and nature of the matrix, and the rate of water uptake. 
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Chapter 7 
 
Drug Release from Microcapsules in 
Biodegradable Poly(lactic-co-glycolic acid) 
Fibres 
 
 
 
7.1 Introduction 
 
Drug-loaded fibres have been widely prepared by electrospinning techniques. 
However, water-soluble drugs are very difficult to incorporate in the process because 
electrospinning requires a full dissolution of all the components in the polymer 
solution1,2. In this Chapter, a new way of incorporating water-soluble drugs into 
PLGA fibres was introduced. Rhodamine 6G (R6G) and bovine serum albumin (BSA) 
were selected as model drugs for the release studies. Trypsin was selected for the 
enzyme activity test. Initially, either R6G, BSA or trypsin was captured within the 
porous calcium carbonate (CaCO3) microparticles by coprecipitation. Microcapsules 
of drug-loaded CaCO3 were also prepared by depositing a layer of poly(sodium 
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4-styrenesulfonate) (PSS) following the technique of LbL polyelectrolyte 
assembling3. Then, these drug-loaded CaCO3 microparticles were mixed in to the 
PLGA solution to form a suspension. By electrospinning the suspension, drug-loaded 
fibres were prepared. The morphology of the fibres produced was studied. The 
structural integrity of the fibre and the drug release curve were investigated in detail 
by SEM and fluorescence spectroscopy. The enzyme activity was tested.  
 
7.2 Experimental 
 
7.2.1 Materials 
 
The PSS (Mw ~ 70,000) and R6G (99 %, Mw = 479) were obtained from Aldrich. The 
BSA (Mw ~ 66,000), trypsin, rhodamine B isothiocyanate (RBITC) and protease 
fluorescent detection kit were acquired from Sigma. PLGA (Resomer LG 857 S with 
i.v. of 5.0-7.0 and LA:GA = 85:15) was purchased from Boehringer Ingelheim 
Pharma GmbH & Co., Germany. All materials were used as supplied without further 
purification. 
 
The water used in all experiments was prepared in a three-stage Millipore Milli-Q 
Plus 185 purification system and had a resistivity higher than 18.2 MΩ cm. 
 
7.2.2 Microparticles Preparation 
 
The conjugation of RBITC with BSA was produced as follows: BSA was dissolved 
in a 0.1 M carbonate buffer, pH 8.5, and RBITC which had been dissolved in 
methanol, was added drop by drop. After 2 days of incubation in the dark under 
constant stirring at 4 ºC, the RBITC-BSA conjugates were purified by dialysis to 
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separate the remaining free RBITC. The RBITC-BSA solution was stored at 4 ºC.  
 
The preparation of all the drug-loaded CaCO3 microparticles was carried out 
according to the coprecipitation method3. Briefly, for BSA-loaded CaCO3 
microparticles, for example, 0.33 M solution of CaCl2, were added to an equal 
volume of a 0.33 M solution of Na2CO3 containing 1.2 mg/ml of RBITC-BSA, 
which were captured by growing CaCO3 microparticles. After intense agitation on a 
magnetic stirrer for 30 sec, the reaction mixture was left without any further stirring 
for 5 min. During this time, the formed amorphous primary precipitate of CaCO3 
slowly transformed into spherical microparticles. Finally, these microparticles were 
centrifuged and triple washed and dried in air. Spherical CaCO3 microparticles with 
an average diameter ranging between 3 to 5 μm were obtained. For the CaCO3 
microcapsules with one layer of PSS coating, mild agitation of the suspension of 
BSA-loaded CaCO3 microparticles in a PSS solution of 2 mg/ml was performed 
using a microshaker for 15 min. The non-bounded PSS was then removed by 
centrifugation, and a triple washing of the precipitate was carried out. The particles 
were stored in the dark at 4 ºC. 
 
For R6G-loaded microparticles, the preparation procedure is the same except 2 
mg/ml of R6G solution was used instead of 1.2 mg/ml of RBITC-BSA. 
 
7.2.3 Electrospinning 
  
The procedure of electrospinning was shown in Fig. 7.1. The spinning solution was 
prepared by dispersing drug-loaded CaCO3 in chloroform first, followed by the 
gradual addition of the PLGA (2 wt.% of chloroform). The drug-loaded CaCO3 was 
added at 2 levels, 5 wt.% and 20 wt.% of the PLGA. An ultrasonic bath was used 
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here to achieve a good dispersion of particles in the solution. The mixture was then 
kept under constant stirring overnight to achieve a full dissolution of the PLGA. The 
electrospinning process was carried out in a horizontal spinning configuration using a 
flat-end needle with a syringe pump producing a steady flow rate of 2 ml/hr at 22 °C 
and 28 % humidity. A collecting aluminium film was placed on a drum rotating at 
100 rpm. The applied voltage was 22 kV. The collected fibre mat was placed in a 
vacuum oven overnight at room temperature to eliminate residual solvents, and then 
stored at 4 °C in the dark for the release study and other characterization analysis. 
 
 
Fig. 7.1 The major steps of electrospinning: (a) loading the drug in CaCO3 
microparticles; (b) the dissolution of PLGA in chloroform with the presence of 
drug-loaded CaCO3 and (c) electrospinning the well mixed solution 
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7.2.4 The Determination of Drug Loading in Fibres 
 
About 2 mg of fibre mat was cut and extracted in 2 ml of 0.1 M NaOH for 12 hr to 
facilitate its full dissolution, and then neutralized by a 1 N HCl solution. The sample 
was centrifuged and the concentration of R6G or BSA in the supernatant was 
determined using a fluorescence spectrometer by the intensity of the peak at 555 nm 
or 595 nm, respectively. The wt.% of drug entrapped was then deduced. Each batch  
was tested in triplicate.  
 
Fluorescence calibration curves were built up to define the relationship between the 
amounts of light absorbed by the solution versus the concentration of the drug 
solution. The BSA and R6G calibration curves are presented in Fig. 7.2. 
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Fig. 7.2 (a) RBITC-BSA and (b) R6G fluorescence calibration curves, showing the 
linear relationship between the drug model concentration and fluorescence intensity 
 
The drug loading was also indirectly calculated according to the wt.% of the drug in 
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the CaCO3 microparticles and the wt.% of particles in the fibres. The drug-loaded 
CaCO3 microparticles were dissolved in 0.1 M HCl and adjusted to pH 7 by NaOH. 
The results produced by both methods were compared.   
 
7.2.5 Drug Release from Fibres 
 
The drug release study was customized by performing in pH 1, 2, 4, 7 release media 
adjusted by HCl. The fibre mat was first cut into 2×2 cm2 squares. Each square 
sample was accurately weighed and placed separately into a 2 ml release medium. 
The test was performed on the microshaker at 50 rpm. At appropriate intervals, 1 ml 
of the supernatant was removed and replenished with an identical volume of fresh 
medium. The drug concentrations were determined by the fluorescence spectrometer 
as described above. Each sample was tested in triplicate. 
 
Drug release profiles were curve-fitted to commonly used models, Higuchi’s 
equation and Korsmeyer and Peppas’ equation, to characterize and derive the drug 
release parameters for comparative purposes. These equations are described in detail 
in Section 5.4.2. 
 
7.2.6 Enzyme Activity Assays 
 
To study the enzyme activity in PLGA fibres, trypsin was coprecipitated with CaCO3 
microparticles and impregnated in the PLGA fibre following the same procedure as 
R6G and BSA. The Bradford reagent was used to determine the concentration of 
trypsin in the solution. The activity of the trypsin enzyme was tested using a protease 
fluorescent detection kit. It uses casein labelled with fluorescein isothiocyanate 
(FITC) as the substrate. Trypsin activity results in the cleavage of FITC-labelled 
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casein substrate into small fragments, which do not precipitate under acidic 
conditions. Therefore, when the mixture is centrifuged, the undigested substrates 
form a pellet and the small, acid soluble fragments remain in the solution. So the 
activity of trypsin can be measured by taking the supernatant (neutralized) and using 
the fluorescence to assay the FITC-labelled fragments at 560 nm.  
 
7.2.7 Morphology Characterization 
 
Both drug-loaded CaCO3 and fibres were examined using optical microscopy 
(Olympus BX-60 using reflected or transmitted light sources with crossed polarizers), 
scanning electron microscopy (SEM) (JEOL 6300TM) and fluorescence microscopy 
(Leica, DMI 4000B, DFC 300FX). Specimens were gold-coated and analysed at a 
voltage of 5 kV for SEM.  
 
7.3 Results and Discussion 
 
7.3.1 Drug-Loaded CaCO3 Microparticles 
 
Drug-loaded CaCO3 microparticles were fabricated by the coprecipitation of CaCO3 
with the drug in the solution. The morphology of the BSA-CaCO3 particles is 
presented in Fig. 7.3. 
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Fig. 7.3 The morphology of BSA-CaCO3 particles (a) SEM image, 10,000×; (b) SEM 
image, 30,000× and (c) fluorescence microscopy   
 
(a) 
(b) 
(c) 
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As it shows, the homogeneous size microparticles were successfully prepared with a 
diameter of around 4 μm (Fig. 7.3a). On closer inspection, highly developed porous 
structures consisting of smaller spherical nanoparticles can be observed (Fig. 7.3b). 
There is no substantial difference between these BSA-CaCO3 and the PSS coated 
BSA-CaCO3 from the observations since the thickness of the PSS layer is only 
around 5nm3. Because the BSA has been labelled with RBITC, the loading of BSA 
can be confirmed easily using fluorescence microscopy (Fig. 7.3c). A bright red 
colour indicates the presence of BSA inside the CaCO3 microparticles. 
 
 
Fig. 7.4 An SEM image of rhombohedral calcite microcrystals of CaCO3 due to the 
recrystallization phenomenon happened in the preparation 
 
The quality of the CaCO3 microparticles strongly depends on the experimental 
conditions, which affect the rate of the nucleation process of CaCO3. It has been 
reported that the growth of the CaCO3 microparticles starts with the forming of an 
amorphous primary precipitate, followed by a colloidal aggregating to form spherical 
micron-sized microparticles, eventually recrystallizing into rhomobohedral calcite 
microcrystals3 (Fig. 7.4). To obtain the homogeneously-sized, non-aggregated, highly 
porous spheres, the experimental conditions need to be carefully controlled to 
preserve the CaCO3 microparticles of spherical morphology before the 
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recrystallization phenomenon occurs. 
 
7.3.2 PLGA Fibres Incorporating Drug-Loaded CaCO3 Microparticles  
 
Drug-loaded CaCO3 microparticles have been successfully incorporated into the 
PLGA fibres. Optical microscopy images confirmed the presence of CaCO3 
microparticles inside the fibres. Rather than single lengths of string, electrospinning 
of the spinning mixture resulted in the formation of a characteristic morphology; a 
bead-and-string structure was clearly achieved (Fig. 7.5).  
 
The 5 % drug-loaded fibres have an average diameter of between 2 and 5 μm. For the 
20 % drug-loaded samples, more microparticles are present along the fibres and the 
thickness of the fibres increases. Under cross polarized illumination, because of the 
refractive index differences between CaCO3 and PLGA, CaCO3 microparticles can be 
seen clearly along the fibres. (Fig. 7.5c) 
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Fig. 7.5 Optical microscopy images of typical PLGA fibres incorporating 
drug-loaded CaCO3 microparticles. (a) 5 % PLGA-BSA-CaCO3 fibres (b) 20 % 
PLGA-BSA-CaCO3 fibres (c) 20 % PLGA-BSA-CaCO3 fibres under cross polarized 
illumination 
 
 
(c) 
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Fig. 7.6 SEM images of (a) 5 % PLGA-R6G-CaCO3 fibres, 1000× (b) 5 % 
PLGA-R6G-CaCO3 fibres, 5000× (c) 5 % PLGA-BSA-CaCO3 fibres (d) 20 % 
PLG-BSA-CaCO3 fibres  
 
The SEM images show that the composite fibre mat has a 3-D structure with a 
random fibre orientation which is evenly distributed on the substrate. (Fig. 7.6a) 
Upon closer inspection, for both R6G-loaded and BSA-loaded fibres, the fibre 
surfaces appear to be highly porous (Fig. 7.6b, c and d). Compared with the 5 % 
BSA-loaded fibres, the sample with 20 % BSA loading shows a significant increase 
of particles along the fibre and an aggregation of the particles was observed. (Fig. 
7.6d) Moreover, very large fibre diameter variations from 1 to 9 μm indicate that the 
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aggregated particles highly influence the stability of the fibre forming process. There 
are no noticeable differences between the PLGA-BSA-CaCO3-PSS fibres and 
PLGA-BSA-CaCO3 fibres in this respect. 
 
 
Fig. 7.7 An SEM image of 5 % PLGA-R6G-CaCO3 fibres produced under 20 % 
humidity 
 
The morphology of electrospun fibres can be influenced by many factors. These 
include the solvent boiling point, surface tension, solution viscosity, solution 
conductivity, solution concentration, glass transition temperature of the polymer, 
applied voltage and the tip to collector distance.4-5 It is believed that the formation of 
the porous structures is a consequence of breath figure and phase separation 
mechanisms. The humidity and temperature of the operation conditions strongly 
influence the porosity of the fibres. One set of 5 % PLGA-R6G-CaCO3 fibres was 
produced under lower humidity, 20 %, instead of 28% for comparison. The fibre 
surfaces hardly had any pores on the surfaces and appeared smoother and much 
denser (Fig. 7.7). Since the morphology of the fibres has a crucial effect on the drug 
release behaviour, the conditions of the electrospinning process were carefully 
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monitored and kept constant throughout.  
 
 
Fig. 7.8 Fluorescence microscopy of (a) 5 % PLGA-R6G-CaCO3 fibres and (b) 5 % 
PLGA-BSA-CaCO3 fibres 
 
Although the differences between R6G-loaded and BSA-loaded fibres are not 
obvious from SEM study, under the fluorescence microscope, R6G-loaded fibre 
emits fluorescence from both the particles inside the fibres and the fibres themselves 
(Fig. 7.8a), whereas the BSA-loaded fibres show much stronger emission from the 
particles and little emission from the fibres (Fig. 7.8b). For R6G-CaCO3 
microparticles, because the R6G molecules are very small (molecular weight ~ 479), 
although R6G has been captured inside CaCO3 microparticles, some of these R6G 
molecules would pass through the pores of the CaCO3 spheres and dissolve in the 
chloroform solvent in the electrospinning process. The presence of R6G in the 
solvent during the electrospinning process determines the stain of the fibres, 
therefore both microparticles and fibres show bright red under fluorescence 
microscopy. On the other hand, RBITC labelled BSA is much bigger (Mw ~ 66,000), 
which can be easily restrained inside the CaCO3 microparticles, and therefore only 
the microparticles show under fluorescent light in this case.  
 
(a) 
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7.3.3 In Vitro Degradation of Fibres 
 
 
Fig. 7.9 SEM with EDX analysis of (a) original 20 % PLGA-6G-CaCO3 fibres and (b) 
PLGA-6G-CaCO3 fibres after release in the pH 1 release medium (3 days) 
 
The progress of degradation of drug-loaded PLGA fibre mats was studied and the 
sample was analysed using SEM with EDX. Fig. 7.9a shows a sample of original 
fibres for comparison. The spectrum on the bead clearly shows the Ca element 
presence in the original fibres (see Fig. 7.9a spectrum 1 and 2), which is not present 
in fibres after release (see Fig. 7.9b spectrum 3 and 4). Table 7.1 provides an 
elemental composition obtained from the EDX analysis. This confirms that 
drug-loaded CaCO3 particles were released from the fibres, leaving the shells behind.  
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Table 7.1 An elemental composition of original 20 % PLGA-6G-CaCO3 fibres and 
sample after release in the pH 1 medium (3 days) (All results in wt.%) 
Spectrum C O Na Si S Cl Ca Total 
 
 
Original 
Spectrum 1 13.94 31.43 0.53 - - 1.02 53.07 100.00
Spectrum 2 21.91 50.53 0.44 - - 0.33 26.80 100.00
Spectrum 3 85.87 13.20 0.35 - 0.58 - - 100.00
Spectrum 4 90.38 9.06 0.16 - 0.19 0.21 - 100.00
 
 
After 
release 
Spectrum 1 79.69 8.03 3.26 - 0.81 8.20 - 100.00
Spectrum 2 90.87 6.14 0.79 0.47 - 1.72 - 100.00
Spectrum 3 86.46 12.99 - 0.55 - - - 100.00
Spectrum 4 90.69 6.58 0.85 0.57 - 1.30 - 100.00
 
Fig. 7.10 illustrates the progress of the degradation of PLGA fibres during the drug 
release test. After being merged in the release medium, the fibres maintained their 
fibrous structure for several days before the fibres’ wall started to look swollen and 
the sharp edges of the pores become indistinct. The bead-and-string structure has 
changed into bag-and-string structure (as circled in Fig. 7.10a). With the passing of 
time, the fibres broke down to smaller segments and these segments broke down to 
even shorter segments (Fig. 7.10c). The pores on the surfaces became bigger and 
started connecting with each other as a consequence of the hydrolytic degradation. 
From the fluorescence microscopy, the decrease in brightness from the fibres and 
microparticles confirms the release of the drug (Fig. 7.10b and d). However, the 
presence of red dots in Fig. 7.10d means that only some of the microparticles had 
been released and that there were still microparticles trapped inside the broken fibre 
segments.  
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Fig. 7.10 The progress of degradation of 20 % PLGA-BSA-CaCO3 fibres exposure to 
pH 4 over time of (a) 9 days, SEM images (b) 9 days, fluorescence microscopy (c) 20 
days, SEM images and (d) 20 days, fluorescence microscopy 
 
The degradation of PLGA has been described as bulk erosion. It has been mentioned 
in Chapter 5 that the acidic microclimate pH inside the PLGA results in the 
acceleration of the degradation process of PLGA6. However, in the case of the 
porous ultrafine fibrous structure of the PLGA, diffusion of degradation products are 
rapid due to the high surface to volume ratio and porosity; therefore, local acidic 
microclimate pH is not presented. The release of CaCO3 microparticles has a 
significant effect on the degradation of PLGA fibres. When the fibre diameter is 
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smaller than the particles, the PLGA fibre wall around the microparticles is believed 
to be very thin; therefore, particles are able to escape first, long before bulk erosion 
happens. The holes left behind allow more water to penetrate the polymer creating a 
new surface area. Moreover, the walls of the holes are the most vulnerable places for 
water absorption, and it is where the breakage of fibres may first happen. Therefore, 
polymer degradation will be accelerated. Whereas when the fibre diameter is larger 
than the incorporated microparticles, these particles are more likely to remain inside 
the fibres, and may even fail to be released even after the bulk erosion of the PLGA 
occurs. The presence of CaCO3 particles has also been reported, acting as pH 
modifiers to buffer the pH of the PLGA matrix, thereby reducing autocatalysis and 
retarding degradation7.  
 
7.3.4 In Vitro Drug Release 
 
To determine the drug loading in the PLGA fibres, two methods were used and data 
are compared in Table 7.2.  
 
Table 7.2 Drug loading in CaCO3 particles and PLGA fibres 
 
Drug  
Drug-loaded 
CaCO3 wt.% in 
PLGA 
Drug wt.% 
in CaCO3 
Deduced drug 
wt.% in PLGA 
Measured drug 
wt.% in PLGA 
R6G 5 0.132  0.0063  0.0018  
BSA 20 2.97  0.50  0.48  
 
For PLGA-R6G-CaCO3 fibres, by the direct extraction of fibres in an NaOH solution, 
the amount of R6G released from these fibres is less than half the amount obtained 
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from the wt.% calculation. It indicates that 70 % of R6G in the CaCO3 microparticles 
were released into the solvent during the electrospinning process and trapped inside 
fibre. Therefore, very little R6G is subsequently released later during the drug release 
test. For BSA-loaded fibres, results from both methods are comparable. Considering 
the Mw of BSA used is as high as 66,000, it is no surprise that almost all the BSA 
molecules are retained inside the CaCO3 microparticles during electrospinning. The 
data from the direct extraction method were used to calculate the drug release, 
because the drug release percentage is proportional to the amount of drug that could 
be released rather than the amount of drug used during the fibre preparation.  
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Fig. 7.11 Drug released in different pH release media (pH=1, 2, 4, 7) (a) 
PLGA-R6G-CaCO3 fibres (b) PLGA-BSA-CaCO3 and (c) PLGA-BSA-CaCO3-PSS 
fibres 
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The release profiles shown in Fig. 7.11 suggest that both the R6G release and the 
BSA release were sustained for 40 days for all the dosage forms. However, a 
complete release of the drug was not achieved by the end of the tests. The initial 
burst was suppressed by encapsulating the drug-loaded CaCO3 microparticles in the 
PLGA fibres. There is no obvious trend for the release curves. The typical biphasic 
phenomena, in which a drug release from the PLGA has been described as an initial 
bursting followed by a late bursting caused by the bulk erosion of PLGA8 is not 
present here. The drug released gradually over time until the test was over. The 
detailed effects of drug type, drug loading and pH of the release medium will be 
discussed below. 
 
7.3.4.1 The Influence of Drug Types 
 
For R6G-loaded fibres, the initial bursting release is dependent on the pH of the 
release medium used and was found to increase with a decrease in pH (Fig. 7.11a). 
For BSA-loaded fibres, little initial bursting was observed from the drug release 
curves (Fig. 7.11b). The initial burst release of R6G is due to the dissolution of R6G 
molecules on the fibre surface, which were deposited during the electrospinning 
process. While BSA molecules were captured inside CaCO3 microparticles, there was 
hardly any leakage thereof. The total amounts of drug released are different for R6G- 
and BSA-loaded samples.  Up to 30 % was achieved for R6G-loaded fibres. For 
BSA loaded samples, 17 % is for PLGA-BSA-CaCO3 fibres and 62 % for 
PLGA-BSA-CaCO3-PSS fibres (sample in pH 4 release medium). The smaller size 
of R6G molecules makes it easier for diffusion by comparison with the BSA 
molecules. However, with a PSS coating around the BSA-loaded CaCO3 
microparticles, the release behaviour becomes complicated. 
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7.3.4.2 The Influence of a PSS Coating of the Microparticles 
 
The PSS coated and uncoated drug releasing systems showed different release 
behaviours. It is not so obvious for the R6G-loaded samples (Figures not shown); 
however, the BSA-loaded samples show a significant increase of BSA release in the 
pH 4 and pH 7 release media (62 % and 56 % respectively in 40 days). Due to the 
hydrophobic nature of PSS and PLGA, during the fibre preparation procedure, the 
interaction between the PSS and PLGA may be strengthened by the outward 
diffusion of PSS into PLGA. PSS is a negatively charged polyelectrolyte. It has been 
considered that BSA is a polyampholyte having the isoelectric point (iep) of 4.59. 
When pH > iep, the net charge of BSA is negative, and for pH < iep, it has a net 
positive charge. There may be interaction between PSS, PLGA and BSA in the pH 4 
and pH 7 release media, which may somehow weaken the structure of CaCO3 
microparticles and facilitate the release of BSA. 
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7.3.4.3 The Influence of Drug Loadings 
  
 
Fig. 7.12 Drug released for PLGA-BSA-CaCO3 fibres in the pH 4 release medium 
 
Drug loading has a considerable effect on the drug release rate. In the case of 20 % 
BSA-loaded samples, the release reached 13 % in 40 days. This is in contrast to 17 % 
for 5 % loading (Fig. 7.12). The increase of the drug loading will increase the 
number of aqueous channels formed by the dissolution of the hydrophilic drug, 
which will act as pathways for further aqueous penetration10. However, the 
dimension of the fibre with 20 % drug loading was much thicker than that of 5 % 
loading, (Fig. 7.6c and d) which could indicate that 20 % drug-loaded fibres entrap 
the incorporated CaCO3 microparticles more deeply inside the fibre, leading to a 
slower release process. In the case here, the slower release received from higher 
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drug-loaded samples indicates that the second factor is dominant. 
 
7.3.4.4 The Influence of the pH of Release Media 
 
For PLGA-R6G-CaCO3 fibres, the release rate increases with the decrease of pH 
with a release of up to 30 % achieved in pH 1. In the case of PLGA-BSA-CaCO3, the 
total amount of BSA released in 40 days is very similar in each release medium.  
For PLGA-BSA-CaCO3-PSS fibres, the BSA release was much more rapid in the pH 
4 and pH 7 media and the total release was as high as 62 % and 56 % respectively in 
40 days.  
 
The pH value plays a significant role in release behaviour, because it is acting on the 
PLGA degradation rate, the dissolution of CaCO3 microparticles and protein stability. 
The strong acidic medium can accelerate the PLGA degradation, as it enhances the 
hydrolysis of the polymer's ester bond linkages11. It also accelerates the dissolution 
of the CaCO3 microparticles. However, a strong acidic solution can cause the 
aggregation of the BSA12. Therefore, R6G-loaded samples showed an increase in 
release in lower pH media due to a faster degradation of the PLGA and the 
dissolution of CaCO3. While for BSA-loaded samples, the effect from aggregation of 
the BSA is so strong that the release of the BSA was heavily suppressed. Lu et al.13 
reported the same phenomenon with growth factor-beta1(TGF-β1) release in 
different pH buffers. For PLGA-BSA-CaCO3-PSS fibres in pH 4 and pH 7, without 
the negative effect from aggregation of the BSA, the releases of BSA were promoted 
by the PSS coating. 
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7.3.4.5 Kinetics of Drug Release 
 
To study the release kinetics, data obtained from the drug release studies were plotted 
against Higuchi’s model and the Korsmeyer and Peppas equation. Data fitted to the 
Higuchi model (Fig. 7.13) showed that R6G-loaded samples had a R2 value of 
0.949-0.977. PLGA-BSA-CaCO3 samples had a higher R2 value of 0.996 and follow 
Higuchi diffusion kinetics. PLGA-BSA-CaCO3-PSS samples in higher pH media 
(pH 4 and pH 7) show slightly lower R2 value of 0.951 and 0.963.  
 
Fig. 7.13 Drug release fitted to Higuchi’s model for drug-loaded samples in the pH 4 
release medium 
 
Release data were also fitted using the equation of Korsmeyer and Peppas (Fig. 7.14). 
The slope of the line gives the value of n, which indicated the release mechanism. 
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For R6G samples, the n value was between 0.33 and 0.48 depending on the pH of the 
release medium. For PLGA-BSA-CaCO3 samples, the n value was around 0.41. Both 
values of n are beyond the range of the model (0.5 ≤ n ≤ 1). It has been mentioned in 
Chapter 6 that drug release from a porous system may lead to n < 0.45. 
PLGA-BSA-CaCO3-PSS samples in higher pH media (pH 4 and pH 7) show an n 
value of 0.64 and 0.62.  
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Fig. 7.14 Drug release fitted to Korsmeyer-Peppas’ model for drug-loaded samples 
in the pH 4 release medium  
 
The R2 values of different models indicate the goodness-of-fit to the type of model to 
which the release data are being fitted. PLGA-BSA-CaCO3 samples follow both 
models well. Other samples do not follow either of the models so well by comparison. 
The complexity of this double incorporated drug system reduces the accuracy of 
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these models. The mechanism of the drug release is complex because it involves the 
diffusion of the drug from the matrices, diffusion of the drug from CaCO3 particles, 
release of the CaCO3 particles, as well as the PLGA degradation. The alterations in 
the polymer phase properties during degradation also bring changes in drug 
diffusivity and permeability with time. Nevertheless, both diffusion and degradation 
are believed to participate in establishing the release pattern.  
 
7.3.5 Enzyme Activity Assays 
 
To study the enzyme activity in PLGA fibres, trypsin was encapsulated in CaCO3 
microparticles and then impregnated into the PLGA fibre following the same 
procedure as R6G and BSA. The results show that the enzyme preserves 70 % of its 
activity after the CaCO3 encapsulation process (Fig. 7.15). However, the fibre 
samples do not show any activity that can be attributed to the trypsin. It may be due 
to the harsh alkaline solution (0.1 M NaOH) used in the dissolution of trypsin-loaded 
fibres, which causes the denaturation of the trypsin. A better enzyme activity test 
needs to be established. 
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Fig. 7.15 The activity of trypsin through the process  
 
7.4 Conclusions  
 
Water-soluble drugs, R6G and BSA, loaded CaCO3 microparticles were successfully 
incorporated in PLGA fibres by a combined coprecipitation and electrospinning 
technique. A bead and string structure of the composite fibre was achieved. The 
initial burst release was restrained because of the presence of CaCO3 microparticles 
as a second barrier. The drug release profile is affected greatly by the drug properties, 
drug loading and pH of the release medium. For R6G-loaded fibres, a release of up to 
30 % was achieved in 40 days and the release rate increased with the decrease of pH. 
For BSA-loaded fibres, a release of up to 19 % was achieved in 40 days. Although a 
strong acidic medium accelerates the degradation of PLGA and dissolution of CaCO3, 
it causes the aggregation of the BSA which suppresses the BSA release. The PSS 
coating of microparticles resulted in a complex release mechanism, resulting in a 
rapid release up to 62 % in the pH 4 medium for the PLGA-BSA-CaCO3-PSS sample. 
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This double barrier drug release system is too complex for the Korsmeyer and 
Peppas model to interpret the drug release mechanisms. Nevertheless, the preparation 
of drug-loaded CaCO3 incorporated fibre structures provides an alternative strategy 
for incorporating water-soluble drugs and proteins in the electrospinning process. 
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Chapter 8 
 
Conclusions and Future Work 
 
 
 
 
 
8.1 Conclusions 
 
This thesis investigated potential improvements in the processing of polymer-based 
systems for enhanced mechanical properties of nanocomposites and for controlled 
drug release in polymer delivery systems. 
 
In Part A, scCO2 assisted mixing was used to process PP/sepiolite or MWNT 
nanocomposites for improved mechanical properties. By comparison with 
nanocomposites processed by traditional melt compounding methods, relatively 
homogeneous dispersed and well separated sepiolite nanoclays were obtained 
throughout the PP matrix for nanocomposites processed in scCO2 even without the 
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aid of PP-g-MA as a compatibilizer. Also, the sepiolite retained its fibre length better 
than in melt compounding. Consequently, the mechanical properties of PP 
nanocomposites prepared in scCO2 were significantly improved, especially without 
the need of PP-g-MA which is a commonly used compatibilizer to aid the dispersion 
of clay in melt compounding. Also for PP/MWNT nanocomposites, a better 
preservation of nanotube lengths in the scCO2 assisted mixing was observed. Good 
dispersions and mechanical properties were achieved with pristine MWNTs, which is 
unlike melt compounding in which improved dispersion and properties can only be 
achieved through the use of HDPE coated MWNTs. For both clays and MWNTs 
nanocomposites, the addition of these nanofillers enhanced the PP nucleation process. 
Apart from the benefits of a lower viscosity of the polymer melt in scCO2 assisted 
mixing, more interestingly, techniques designed to achieve high quality PP 
nanocomposites, such as the use of masterbatches, PP-g-MA compatibilizer or 
polymer coated nanofillers were not needed when using scCO2 assisted mixing. This 
is very encouraging from a technological and economical point of view. 
 
Part B focused on the development of polymer sustained release devices for 
controlled drug release. The traditional cured non-degradable polymer system, 
CX-PEM/THFM, was modified by the ScCO2 foaming technique for an optimum 
CX release. Highly porous structures were successfully produced and the level of CX 
released from scCO2 foamed samples was 3 times higher by comparison with the 
traditionally cured sample. Moreover, the drug release rate was tailored by altering 
the processing conditions, such as the CO2 saturation time and the depressurization 
time. A significant improvement was also made for a biodegradable polymer PLGA 
fibre system. Here, the layer by layer encapsulation technique was used to trap 
water-soluble drugs inside CaCO3 microparticles before carrying out the 
electrospinning process. The water-soluble drugs, R6G or BSA, loaded CaCO3 
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microparticles were successfully incorporated into the PLGA fibres. A bead and 
string structure of the composite fibre was achieved. The initial burst release due to 
the dissolution of the drug present on the surface was clearly restrained. The drug 
release from this system is complicated and is affected greatly by the drug’s 
properties, drug loading and pH of the release medium. The mechanisms of the drug 
release involved both diffusion and degradation. However, common kinetic models, 
Higuchi’s equation and Korsmeyer and Peppas’ equation, did not give a clear insight 
into the drug release mechanisms.  
 
8.2 Future Work 
 
The viscosity of a polymer melt is a crucial factor in the polymer/filler mixing 
process. In scCO2 assisted mixing, CO2 dissolved in the polymer will cause a 
reduction of viscosity as mentioned in Chapter 2. It affects the productivity, 
operating conditions and the properties of the final products. It will be interesting to 
investigate the relationship between the reduction in viscosity of the PP melt and the 
final dispersion results. However, it is very difficult to measure the viscosity of a 
polymer/scCO2 solution using conventional rheometers such as a capillary rheometer 
or a rotational rheometer because of the vaporization of CO2. In literature, some 
equipments have been successfully designed for the measurement. A special loading 
assembly and a back pressure assembly into a plunger type capillary rheometer have 
been introduced by Mendelson1 and Gerhardet et al.2. An online measurement of 
polymer/gas solution viscosities was also designed using capillary dies and a wedge 
die attached to a single screw or twin screw extrusion systems3. 
 
From an industrial point of view, to achieve the continuous production of polymer 
nanocomposites, it is essential to apply a scCO2 assisted extrusion process. CO2 
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needs to be fed continuously into the molten polymer stream in a modified extruder. 
In order to ensure a single-phase polymer/scCO2 solution, a special extruder setup 
incorporating a CO2 injection device needs to be designed for generating the high 
pressures involved. Also, the extruder requires modifications in its screw 
configuration to avoid the leakage of CO2. An example of a modified extruder is 
suggested in Fig. 8.1. There have been various attempts to incorporate scCO2 into 
continuous processing systeme. Garcia-Leiner4 reported using a modified single 
screw extruder with a scCO2 injection near the feed hopper for processing 
PE/montmorillonite nanocomposites. Treece and Oberhauser5 modified a single 
screw extrusion with direct scCO2 feed to the extruder barrel. A twin screw extruder 
has been investigated by Hwang et al.6 with scCO2 being injected directly into the 
mid-stream to produce the PP/clay nanocomposites.  
 
 
Fig. 8.1 A schematic setup of a scCO2 assisted extruder process system 
 
For the CX-PEM/THFM drug system, the great potential of enhanced drug release 
has been shown with the scCO2 foamed systems. In terms of future work, it would be 
interesting to investigate the water uptake of the samples during drug release. It has 
been mentioned in Chapter 5 that THFM has an unusual water uptake behaviour. 
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Poly(THFM) absorbs 50 % water when the polymer is immersed in water per se.7. 
Because the drug release begins with the absorption of water into the polymer matrix 
and the water uptake can also cause a change in mass and/or volume of the 
polymer/drug system, the drug release behaviour may be influenced by its water 
uptake. Water uptake of the traditional cured CX-PEM/THFM has been measured by 
Patel et al.7. The results showed that the PEM/THFM absorbed 12 % water whilst a 
CX-PEM/THFM (12 wt.% CX) system absorbed 22 % water in 6 months. It 
indicated that CX promotes the water uptake of the system. It will be of research 
interest to compare these data with that of the scCO2 foamed CX-PEM/THFM 
system and to investigate the contribution of the water uptake to the final drug 
release behaviour. In terms of the applications of this porous system, it is likely to be 
commercialized as a drug-loaded denture for antifungal and anti-infection purposes. 
Apart from CX, antifungal agents such as Amphotricin B, fluconazole, nystatin can 
also be applied in the system8.  
 
Regarding the PLGA fibres that incorporate drug-loaded CaCO3 microparticles, the 
measurement of the bioactivity of the drugs after being incorporated inside the fibre 
is a major issue. Since the optimum pH of trypsin is 8, the conformation of trypsin is 
well ordered between pH 7 and 8, but is considerably less well ordered at more 
acidic or alkaline pH values9.  It may be possible to use different dissolution agents 
instead of 0.1 M NaOH which are mild to trypsin. Alternatively, some organic 
solvents may be used to dissolve the PLGA as long as it is not reactive with trypsin. 
Organic solvents have been employed to dissolve PLGA including ethyl acetate, 
NMP, benzyl alcohol, triacetin, benzyl benzoate, 2-pyrrolidone, PEG, 
dichloromethane, DMSO, chloroform, etc. The efficiency of the dissolution depends 
on the ratio of PGA and PLA, and the solubility parameter of the solvent. On the 
other hand, instead of trypsin, other enzymes which have a wider range of pH 
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stability maybe used.  
 
Moreover, a single layer of PSS was coated outside the drug loaded CaCO3 
microparticles to study the drug release behavior. It makes sense to deposit multiple 
layers using the common electrolyte combination of PSS and PAH in order to study 
the influence of a different number of layers on the final drug release.  
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